<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="jbio70005" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biophotonics</journal-id><journal-id journal-id-type="iso-abbrev">J Biophotonics</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">JBIO</journal-id><journal-title-group><journal-title>Journal of Biophotonics</journal-title></journal-title-group><issn pub-type="ppub">1864-063X</issn><issn pub-type="epub">1864-0648</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12162170</article-id><article-id pub-id-type="pmcid-ver">PMC12162170.1</article-id><article-id pub-id-type="pmcaid">12162170</article-id><article-id pub-id-type="pmcaiid">12162170</article-id><article-id pub-id-type="pmid">40083278</article-id><article-id pub-id-type="doi">10.1002/jbio.70005</article-id><article-id pub-id-type="publisher-id">JBIO70005</article-id><article-id pub-id-type="other">jbio.202400479.R3</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Combination of Active&#8208;Targeted Photodynamic Therapy and Photoactivated Chemotherapy for Enhanced&#160;Cancer Treatment</article-title></title-group><contrib-group><contrib id="jbio70005-cr-0001" contrib-type="author"><name name-style="western"><surname>Nkune</surname><given-names initials="NW">Nkune Williams</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3746-707X</contrib-id><xref rid="jbio70005-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jbio70005-cr-0002" contrib-type="author" corresp="yes"><name name-style="western"><surname>Abrahamse</surname><given-names initials="H">Heidi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5002-827X</contrib-id><xref rid="jbio70005-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>habrahamse@uj.ac.za</email></address></contrib></contrib-group><aff id="jbio70005-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Laser Research Centre, Faculty of Health Sciences</named-content>
<institution>University of Johannesburg</institution>
<city>Doornfontein</city>
<country country="ZA">South Africa</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Heidi Abrahamse (<email>habrahamse@uj.ac.za</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2025</year></pub-date><volume>18</volume><issue seq="40">6</issue><issue-id pub-id-type="pmc-issue-id">490437</issue-id><issue-id pub-id-type="doi">10.1002/jbio.v18.6</issue-id><elocation-id>e70005</elocation-id><history><date date-type="rev-recd"><day>26</day><month>2</month><year>2025</year></date><date date-type="received"><day>30</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>28</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-13 17:25:29.683"><day>13</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Journal of Biophotonics</italic> published by Wiley&#8208;VCH GmbH.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JBIO-18-e70005.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:JBIO-18-e70005.pdf"/><abstract><title>ABSTRACT</title><p>Scientists have been actively investigating novel therapies that can effectively eradicate cancer cells with negligible side effects in normal tissues when used alone or in a combinatorial approach. Photodynamic therapy has emerged as a promising non&#8208;invasive therapy that integrates photosensitizer, oxygen, and a specific wavelength of light for the treatment of cancer. Despite encouraging outcomes yielded by PDT, conventional PSs are faced with longstanding challenges such as poor water solubility, a short half&#8208;life, and off&#8208;target toxicity. Development of nanotherapeutics has shown great potential in overcoming this issue. The tumor microenvironment is inherently hypoxic, and this promotes tumor resistance to PDT, as it is oxygen&#8208;dependent. Photoactivated chemotherapy, an oxygen&#8208;independent light&#8208;based therapy, utilizes chemotherapeutic regimens that remain inert until exposed to light, allowing target&#8208;specific activation while minimizing off&#8208;target toxicity. Integration of these techniques can improve selectivity and yield synergistic cytotoxic effects that could improve cancer treatment.</p></abstract><abstract abstract-type="graphical"><p>Photoactivated chemotherapy (PACT), an oxygen&#8208;independent light&#8208;based therapy, utilizes chemotherapeutic regimens that remain inert until exposed to light, allowing target&#8208;specific activation while minimizing off&#8208;target toxicity. The integration of these techniques has the potential to improve selectivity and yield synergistic cytotoxic effects that could improve cancer treatment.<boxed-text position="anchor" content-type="graphic" id="jbio70005-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="JBIO-18-e70005-g005.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jbio70005-kwd-0001">cancer</kwd><kwd id="jbio70005-kwd-0002">hypoxia</kwd><kwd id="jbio70005-kwd-0003">nanotechnology</kwd><kwd id="jbio70005-kwd-0004">photoactivated chemotherapy</kwd><kwd id="jbio70005-kwd-0005">photodynamic therapy</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Research Foundation
</institution><institution-id institution-id-type="doi">10.13039/501100001321</institution-id></institution-wrap></funding-source><award-id>98337</award-id></award-group><award-group id="funding-0002"><funding-source>South African Research Chairs Initiative of the Department of Science and Technology</funding-source></award-group></funding-group><counts><fig-count count="7"/><table-count count="4"/><page-count count="15"/><word-count count="10300"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.7 mode:remove_FC converted:12.06.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="jbio70005-ntgp-0001"><fn fn-type="funding" id="jbio70005-note-0001"><p>
<bold>Funding:</bold> This work is based on the research supported by the South African Research Chairs Initiative of the Department of Science and Technology and the National Research Foundation of South Africa (Grant no. 98337).</p></fn></fn-group></notes></front><body id="jbio70005-body-0001"><sec id="jbio70005-sec-0001"><label>1</label><title>Introduction</title><p>Cancer remains a daunting public health issue that claims approximately 8.2 million lives globally. By 2030, projections indicate that cancer will cause over 13.1 million deaths worldwide, making it the second&#8208;leading cause of death after cardiovascular disorders [<xref rid="jbio70005-bib-0001" ref-type="bibr">1</xref>]. Current therapeutic interventions for treating cancer include chemotherapy, surgery, and radiotherapy. However, these modalities are impeded by complications relating to bone marrow suppression, gastrointestinal tract issues, hepatic and renal toxicity, and cardiac impairment [<xref rid="jbio70005-bib-0002" ref-type="bibr">2</xref>]. Furthermore, medicinal treatments rarely yielded an appreciable prognosis in patients due to the heterogenicity of cancers and the development of therapy resistance mechanisms [<xref rid="jbio70005-bib-0002" ref-type="bibr">2</xref>, <xref rid="jbio70005-bib-0003" ref-type="bibr">3</xref>]. Surgery is closely associated with mortality and morbidity, hampering quality of life [<xref rid="jbio70005-bib-0002" ref-type="bibr">2</xref>]. The search for alternative treatments remains imperative to improve the prognosis and quality of life of patients without attenuating therapeutic efficacy. Photodynamic therapy (PDT) has been under intense investigation due to its non&#8208;invasiveness and increased potency. PDT is based on the integration of three essentials: PS, light with a suitable wavelength, and the availability of molecular oxygen [<xref rid="jbio70005-bib-0004" ref-type="bibr">4</xref>]. The PDT reaction begins with the absorption of the PS by tumor tissues, followed by its activation using a specific wavelength of light, which leads to a series of photochemical reactions that exert cytotoxic activity in cancer cells due to the generation of reactive oxygen species (ROS) [<xref rid="jbio70005-bib-0005" ref-type="bibr">5</xref>].</p><p>In recent years, scientists have been actively engaged to improving the effectiveness and target&#8208;specificity of cancer therapies. In relation to PDT, the hydrophobic nature of PSs causes them to aggregate in aqueous conditions, thereby drastically hampering the efficacy of PDT [<xref rid="jbio70005-bib-0006" ref-type="bibr">6</xref>, <xref rid="jbio70005-bib-0007" ref-type="bibr">7</xref>]. In addition, PSs cannot exclusively differentiate between tumor cells and healthy tissues due to their poor specific affinity for tumor cells, so adjacent healthy tissues may be affected during treatment. In this instance, the integration of nanotechnology and PDT holds great promise for addressing the challenges [<xref rid="jbio70005-bib-0007" ref-type="bibr">7</xref>]. Oxygen is an indispensable element for initiating the PDT mechanism of action. However, the excessive proliferation of cancer cells leads to a hypoxic microenvironment of cancer cells, which drastically stifles the PDT activity&#160;[<xref rid="jbio70005-bib-0008" ref-type="bibr">8</xref>]. Therefore, recent studies have pointed out that hypoxia is a hallmark characteristic of tumor tissue, which significantly reduces intracellular ROS yield [<xref rid="jbio70005-bib-0009" ref-type="bibr">9</xref>]. During the process of PDT, the increased usage of PDT may further exacerbate tumor hypoxia, even leading to reduced PDT overall efficacy [<xref rid="jbio70005-bib-0008" ref-type="bibr">8</xref>, <xref rid="jbio70005-bib-0009" ref-type="bibr">9</xref>]. Therefore, the combination of PDT with oxygen&#8208;dependent modalities is one of the main strategies to improve cancer treatment through synergistic effects.</p><p>PACT is a promising light&#8208;based cancer treatment that has garnered a lot of attention due to its increased selectivity and negligible side effects. Contrary to PDT, PACT is oxygen&#8208;independent and more effective for treating hypoxic tumors [<xref rid="jbio70005-bib-0010" ref-type="bibr">10</xref>]. PACT agents undergo a photoinduced change in their chemical formula upon irradiation, which in turn releases cytotoxic compounds that are independent of oxygen in tumor cells [<xref rid="jbio70005-bib-0011" ref-type="bibr">11</xref>]. Table&#160;<xref rid="jbio70005-tbl-0001" ref-type="table">1</xref> summarizes the differences between PDT and PACT. In this review, we examine the potential combination of photoactive agents that could be used in PDT and PACT therapies to produce anticancer synergistic effects in tumor cells, thereby eliminating resistance and hypoxic tumors that are unresponsive to PDT alone.</p><table-wrap position="float" id="jbio70005-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Photodynamic therapy versus photoactivated chemotherapy.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="bottom" rowspan="1" colspan="1">Photodynamic therapy</th><th align="center" valign="bottom" rowspan="1" colspan="1">Photoactivated chemotherapy</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Oxygen dependence</td><td align="center" valign="top" rowspan="1" colspan="1">Less effective in low oxygen concentrations</td><td align="center" valign="top" rowspan="1" colspan="1">Remains effective in hypoxic conditions</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0012" ref-type="bibr">12</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Stoichiometry</td><td align="center" valign="top" rowspan="1" colspan="1">Catalytic</td><td align="center" valign="top" rowspan="1" colspan="1">Stoichiometric</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0013" ref-type="bibr">13</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mechanism of action</td><td align="center" valign="top" rowspan="1" colspan="1">Generates cytotoxic singlet oxygen and ROS</td><td align="center" valign="top" rowspan="1" colspan="1">Activates prodrugs to release cytotoxic agents</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0014" ref-type="bibr">14</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Clinical application</td><td align="center" valign="top" rowspan="1" colspan="1">Superficial tumors</td><td align="center" valign="top" rowspan="1" colspan="1">Deep&#8208;seated tumors</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0015" ref-type="bibr">15</xref>, <xref rid="jbio70005-bib-0016" ref-type="bibr">16</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cost and availability</td><td align="center" valign="top" rowspan="1" colspan="1">Cheap and widely available</td><td align="center" valign="top" rowspan="1" colspan="1">Expensive and limited availability</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0017" ref-type="bibr">17</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Drug type</td><td align="center" valign="top" rowspan="1" colspan="1">Photosensitizers</td><td align="center" valign="top" rowspan="1" colspan="1">Photoactivated prodrugs</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0018" ref-type="bibr">18</xref>]</td></tr></tbody></table></table-wrap></sec><sec id="jbio70005-sec-0002"><label>2</label><title>Photodynamic Therapy</title><p>PDT is a clinically proven advancement in cancer treatment that has garnered significant attention as a potential method of cancer treatment over time [<xref rid="jbio70005-bib-0019" ref-type="bibr">19</xref>]. Unlike conventional therapies, PDT is less invasive and demonstrates a strong cytotoxic affinity for malignant cells versus healthy tissues. PDT directly induces cell death via various modes of cell death mechanisms, namely apoptosis, necrosis, and autophagy, which can considerably improve the quality of life and prognosis of cancer patients [<xref rid="jbio70005-bib-0004" ref-type="bibr">4</xref>, <xref rid="jbio70005-bib-0020" ref-type="bibr">20</xref>]. Hence, PDT has gained popularity in cancer treatment.</p><sec id="jbio70005-sec-0003"><label>2.1</label><title>Mechanism of Action and Modes of Cell Death Induction</title><p>To eradicate cancer cells via oxidative stress, the PDT process requires the optimum integration of a specific wavelength, a PS, and tumor molecular oxygen. The success of this treatment hinges on the PS molecule, which can be selectively retained in target cells or tissues relative to surrounding normal tissues upon systemic or local administration [<xref rid="jbio70005-bib-0021" ref-type="bibr">21</xref>]. Once the optimal dose of PS is retained, the targeted tissues can then be illuminated with visible light for a predetermined exposure period. When exposed to light corresponding to its action spectrum, the PS transitions from the ground state (single state) to the excited state (triplet state) [<xref rid="jbio70005-bib-0022" ref-type="bibr">22</xref>]. In this triplet state, PS combines with molecular oxygen to form reactive oxygen species via two mechanisms [<xref rid="jbio70005-bib-0007" ref-type="bibr">7</xref>]. Type I involves the PS interacting with biomolecules via a transfer of hydrogen atoms to form radicals, which then react with molecular oxygen to produce ROS. Whereas in a type II reaction, ions and energy directly react with oxygen to generate extremely oxidizing singlet oxygen (<sup>1</sup>O<sub>2</sub>) [<xref rid="jbio70005-bib-0023" ref-type="bibr">23</xref>]. However, the initiation of the aforementioned mechanisms is influenced by various factors, such as the oxygen level, pH, and the configuration of the PS. When all the oxygen is consumed, the type II mechanism thrives [<xref rid="jbio70005-bib-0024" ref-type="bibr">24</xref>]. Figure&#160;<xref rid="jbio70005-fig-0001" ref-type="fig">1</xref> depicts the rationale behind PDT.</p><fig position="float" fig-type="FIGURE" id="jbio70005-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Illustration of photodynamic therapy mechanism of action.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="JBIO-18-e70005-g003.jpg"/></fig><p>The photodamaging activity of PDT is attributed to three mechanisms, such as ROS&#8208;induced tumor cell death, antitumor immune responses, and tumor&#8208;related vascular system vascular destruction. PDT destroys cancer cells predominantly via apoptosis, necrosis, or autophagy [<xref rid="jbio70005-bib-0025" ref-type="bibr">25</xref>]. The occurrence of different types of cell death depends on the accumulation of PS within the cell. The destruction of the mitochondria triggers apoptosis; cell membrane disruption and loss of integrity evoke necrosis; and impairment of the lysosomes or reticulum causes autophagy [<xref rid="jbio70005-bib-0007" ref-type="bibr">7</xref>]. Moreover, the efficacy of PDT is also influenced by its ability to evoke systemic antitumor immune reactions. PDT destroys the architecture of the tumor, allowing cancer cells and immune cells to interact directly. The direct destruction of tumor tissue elicits a potent inflammatory reaction, and leukocytes infiltrate the tumor, stimulating a significant release of inflammatory mediators [<xref rid="jbio70005-bib-0026" ref-type="bibr">26</xref>]. The overall PDT outcomes largely hinge on the choice of PS based on its characteristics related to solubility and target&#8208;selectivity [<xref rid="jbio70005-bib-0007" ref-type="bibr">7</xref>].</p></sec><sec id="jbio70005-sec-0004"><label>2.2</label><title>Photosensitizers</title><p>PSs are molecules that demonstrate light&#8208;sensitive chemical and/or physical reactions when excited with light correlating with their absorption spectrum [<xref rid="jbio70005-bib-0019" ref-type="bibr">19</xref>]. Ideally, A PS should be inactive in the dark, exhibit high chemical purity, selectively accumulate in the target tissue, be readily available and cost&#8208;effective, remain stable at room temperature, be effectively eliminated from the body, exhibit a short drug&#8211;light interval, and effectively generate singlet oxygen upon irradiation [<xref rid="jbio70005-bib-0007" ref-type="bibr">7</xref>]. Photofrin and hematoporphyrin are categorized as the first&#8208;generation PSs [<xref rid="jbio70005-bib-0027" ref-type="bibr">27</xref>]. Photofrin remains the widely used PS, which has been approved for the treatment of various cancers, such as cervical cancer, lung cancer, bladder cancer, and esophageal cancer. However, this PS cannot reach its full potential in clinical trials due to drawbacks related to low chemical purity, skin hypersensitivity, and poor absorption in the therapeutic window [<xref rid="jbio70005-bib-0006" ref-type="bibr">6</xref>].</p><p>These issues compelled researchers to develop second&#8208;generation PSs with greater chemical purity, a higher singlet oxygen yield, and enhanced tissue penetration depth due to their strong absorption in the therapeutic window. Furthermore, they exhibit negligible side effects due to their higher affinity for cancer tissues and rapid clearance from the body [<xref rid="jbio70005-bib-0028" ref-type="bibr">28</xref>]. Several classes of PS have been the subject of extensive research for PDT applications, such as phthalocyanine derivatives, anthraquinone derivatives, porphyrin derivatives, chlorin&#8208;e6 derivatives, and photofrin derivatives [<xref rid="jbio70005-bib-0029" ref-type="bibr">29</xref>]. In recent years, third&#8208;generation PSs have garnered significant attention due to their great potential to alleviate the limitations of conventional PSs (poor efficacy, off&#8208;target toxicity, and poor light absorption rate) as they can selectively accumulate in target tissues while sparing normal tissues, which is attributed to their modification with inherently hydrophilic nanomaterials [<xref rid="jbio70005-bib-0030" ref-type="bibr">30</xref>]. Most PSs are intrinsically hydrophobic, thereby tending to aggregate with other molecules in an aqueous setting [<xref rid="jbio70005-bib-0031" ref-type="bibr">31</xref>]. Therefore, combining these PSs with nanomaterials, including hydrophilic polymers, circumvents this issue. Furthermore, nanomaterials not only alleviate the aggregation of PSs but also prevent their premature degradation before reaching tumor regions, thereby increasing their bioavailability and efficient drug delivery [<xref rid="jbio70005-bib-0032" ref-type="bibr">32</xref>]. Table&#160;<xref rid="jbio70005-tbl-0002" ref-type="table">2</xref> gives an overview of several promising PSs that have garnered significant attention in the clinical setting [<xref rid="jbio70005-bib-0025" ref-type="bibr">25</xref>, <xref rid="jbio70005-bib-0033" ref-type="bibr">33</xref>].</p><table-wrap position="float" id="jbio70005-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>PSs that have been explored in the clinical setting.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Photosensitizer</th><th align="center" valign="bottom" rowspan="1" colspan="1">Approval</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cancer type</th><th align="center" valign="bottom" rowspan="1" colspan="1">Wavelength (nm)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">5&#8208;Aminolevulinic acid (5&#8208;ALA, Levulan)</td><td align="center" valign="top" rowspan="1" colspan="1">Worldwide</td><td align="center" valign="top" rowspan="1" colspan="1">Actinic keratosis</td><td align="center" valign="top" rowspan="1" colspan="1">635</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Methyl aminolevulinate (Metvix)</td><td align="center" valign="top" rowspan="1" colspan="1">Worldwide</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Talaporfin sodium/NPe6 (Laserphyrin)</td><td align="center" valign="top" rowspan="1" colspan="1">Japan</td><td align="center" valign="top" rowspan="1" colspan="1">Lung cancer</td><td align="center" valign="top" rowspan="1" colspan="1">664</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bremachlorin (Radachlorin)</td><td align="center" valign="top" rowspan="1" colspan="1">Russia</td><td align="center" valign="top" rowspan="1" colspan="1">Sarcoma, nasopharyngeal, brain</td><td align="center" valign="top" rowspan="1" colspan="1">660</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Temoporfin/mTHPC (Foscan)</td><td align="center" valign="top" rowspan="1" colspan="1">Europe</td><td align="center" valign="top" rowspan="1" colspan="1">Head and neck, brain, skin, lung, bile</td><td align="center" valign="top" rowspan="1" colspan="1">652</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Verteporfin (Visudyne)</td><td align="center" valign="top" rowspan="1" colspan="1">Worldwide</td><td align="center" valign="top" rowspan="1" colspan="1">Skin, ophthalmic, pancreatic</td><td align="center" valign="top" rowspan="1" colspan="1">690</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Porfimer sodium (photofrin)</td><td align="center" valign="top" rowspan="1" colspan="1">Worldwide</td><td align="center" valign="top" rowspan="1" colspan="1">Lung, brain, esophagus, bile duct, ovarian</td><td align="center" valign="top" rowspan="1" colspan="1">630</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hexaminolevulinate hydrochloride (Cysview)</td><td align="center" valign="top" rowspan="1" colspan="1">USA, Europe, Canada</td><td align="center" valign="top" rowspan="1" colspan="1">Bladder cancer detection</td><td align="center" valign="top" rowspan="1" colspan="1">360&#8211;450</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Redaporfin (LUZ 11)</td><td align="center" valign="top" rowspan="1" colspan="1">Pending approval in Europe</td><td align="center" valign="top" rowspan="1" colspan="1">Bile duct</td><td align="center" valign="top" rowspan="1" colspan="1">749</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Padoporfin (TOOKAD)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Prostate cancer</td><td align="center" valign="top" rowspan="1" colspan="1">762</td></tr></tbody></table></table-wrap></sec><sec id="jbio70005-sec-0005"><label>2.3</label><title>Nanotechnology in Photodynamic Therapy</title><p>In recent years, nanoparticles (NPs) have been extensively investigated in the field of PDT to address various challenges hindering its progress in both preclinical and clinical studies. NPs are commonly described as submicroscopic particles with dimensions ranging from 1 to 100&#8201;nm. They are derived from a wide range of naturally occurring or synthetic materials and can be designed as cargo for various theranostic agents in a targeted manner [<xref rid="jbio70005-bib-0003" ref-type="bibr">3</xref>]. NPs are endowed with large surface&#8208;to&#8208;volume ratios, which allow for effective delivery of adequate amounts of PS at targeted regions [<xref rid="jbio70005-bib-0034" ref-type="bibr">34</xref>]. They may prevent untimely PS release and its potential for inactivation by biological barriers, thereby preventing unwanted accumulation in healthy tissues, and reducing overall photosensitivity [<xref rid="jbio70005-bib-0035" ref-type="bibr">35</xref>]. NPs improve the amphilicity of PSs, which allows them following freely travel through the bloodstream and localize in the tumorous tissue [<xref rid="jbio70005-bib-0036" ref-type="bibr">36</xref>]. They typically capitalize on the enhanced permeability and retention (EPR) effect, a phenomenon attributed to impaired and leaky tumor neovasculature and poor lymphatic drainage of the tumor, which promotes both the diffusion of PS nanocarriers into and absorption by tumor tissue [<xref rid="jbio70005-bib-0037" ref-type="bibr">37</xref>]. Furthermore, their highly modifiable surface chemistry facilitates the attachments of targeting moieties (i.e., antibodies, peptides, folic acid, and carbohydrates), which enhances biodistribution, pharmacokinetics, cellular uptake, and target&#8208;selectivity [<xref rid="jbio70005-bib-0038" ref-type="bibr">38</xref>]. They can be formulated as multifunctional nanocarriers that carry diverse components, such as imaging agents and chemotherapeutics, which allow for effective combinatorial regimens for cancer treatment [<xref rid="jbio70005-bib-0039" ref-type="bibr">39</xref>]. Various nanocarrier systems have been used in PDT applications, such as liposomes, dendrimers, nanomicelles, upconversion NPs, metal&#8211;organic, mesoporous silica, graphene&#8208;based nanomaterials, and metal&#8211;organic frameworks [<xref rid="jbio70005-bib-0007" ref-type="bibr">7</xref>].</p></sec><sec id="jbio70005-sec-0006"><label>2.4</label><title>Active&#8208;Targeted Nanocarrier Delivery Systems in Photodynamic Therapy Applications</title><p>Nanocarrier systems can promote either passive or active localization of PS in tumor regions Figure&#160;<xref rid="jbio70005-fig-0002" ref-type="fig">2</xref>. PS incorporated in NPs (passive uptake) are not target&#8208;specific and, to some extent, accumulate in adjacent normal tissues [<xref rid="jbio70005-bib-0040" ref-type="bibr">40</xref>]. In order to tackle these problems, nanocarriers are modified with targeting moieties for precise spatial control in&#160;vivo, thereby enhancing the effectiveness of PS molecules compromised by passive accumulation and their incapacity to differentiate between tumor cells and normal cells. Various biomarkers are exclusively or highly expressed on the surfaces of cancer cells, and the incorporation of ligand onto the surface of the nanocarrier systems can effectively identify tumor cells by binding to these markers, which will significantly mitigate collateral damage to healthy neighboring tissues [<xref rid="jbio70005-bib-0041" ref-type="bibr">41</xref>]. Active&#8208;targeting is facilitated by receptor&#8208;mediated endocytosis, which enhances the internalization of nanocarriers by cancer cells, consequently improving PS bioavailability within the cells [<xref rid="jbio70005-bib-0038" ref-type="bibr">38</xref>].</p><fig position="float" fig-type="FIGURE" id="jbio70005-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Passive and active&#8208;targeted delivery techniques.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="JBIO-18-e70005-g001.jpg"/></fig><p>Several studies have shown promising results with active&#8208;targeted nanocarrier delivery systems in PDT applications. Shi et&#160;al. [<xref rid="jbio70005-bib-0042" ref-type="bibr">42</xref>] investigated the phototoxic effect of diiodostyryl bodipy&#8208;conjugated hyaluronic acid NPs (DBHA&#8208;NPs) on colon cancer cells in&#160;vivo. DBHA&#8208;NPs significantly inhibited tumor growth due to their target selectivity and EPR effect. Wang et&#160;al. [<xref rid="jbio70005-bib-0043" ref-type="bibr">43</xref>] modified pyropheophorbide (Pyro) with folic acid and reported that this conjugated Pyro showed remarkable PDT efficacy due to improved cellular uptake of Pyro compared to free Pyro. Similar observations were also reported in ovarian cancer [<xref rid="jbio70005-bib-0044" ref-type="bibr">44</xref>]. Another study evaluated the efficacy of hypericin&#8208;loaded transferrin nanoformulations on colorectal cancer cells. The nanoformulation was stable during PDT and significantly yielded cytotoxic ROS compared to free hypericin [<xref rid="jbio70005-bib-0045" ref-type="bibr">45</xref>]. Pan et&#160;al. [<xref rid="jbio70005-bib-0046" ref-type="bibr">46</xref>] designed a photoactive antibody&#8208;Chlorin e6 conjugate to target tumor cells in&#160;vitro and in&#160;vivo. Both in&#160;vitro and in&#160;vivo studies demonstrated that the conjugate could rapidly and efficiently target tumors, generate ROS, and destroy tumor cells. In addition, Li et&#160;al. [<xref rid="jbio70005-bib-0047" ref-type="bibr">47</xref>] investigated the effect of a nanocarrier system composed of indocyanine green (ICG), hollow gold nanospheres, and TNYL peptide to actively target EphB4 receptors expressed by CT&#8208;26 tumor cells. Li and colleagues noted that the nanoconjugate showed an increased accumulation in CT&#8208;26 tumor cells compared to free ICG.</p><p>A year later, Li and colleagues [<xref rid="jbio70005-bib-0048" ref-type="bibr">48</xref>] conjugated pyropheophorbide (Pyro), a cyclic cRGDfK (cRGD) peptide, which significantly increased the targeted&#8208;specificity of Pyro and its tumoricidal effects in murine models versus unbound Pyro. Table&#160;<xref rid="jbio70005-tbl-0003" ref-type="table">3</xref> summarizes active&#8208;targeted nanocarrier systems that have shown promising results in PDT applications. Despite the promising results shown by active&#8208;targeted nanocarrier systems, the hypoxic nature of solid cancer remains a daunting challenge for PDT efficacy. The scarcity of O<sub>2</sub>, the most paramount fundamental of the PDT process, which serves as the main facilitator for the energy transfer light, can significantly reduce phototoxic damage through singlet oxygen generation and therefore lower the therapeutic efficacy [<xref rid="jbio70005-bib-0049" ref-type="bibr">49</xref>]. Therefore, it remains imperative to circumvent this issue by integrating PDT with modalities that are not reliant on O<sub>2</sub> to function so that they are supplementary when oxygen in the tumor depletes during the PDT process.</p><table-wrap position="float" id="jbio70005-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Various active&#8208;targeted nanoplatforms explored in cancer therapy using photodynamic therapy.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Targeting biomolecule</th><th align="center" valign="bottom" rowspan="1" colspan="1">PS&#8208;nanocarrier</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cancer</th><th align="center" valign="bottom" rowspan="1" colspan="1">Outcome</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">cRGDyk peptide</td><td align="center" valign="top" rowspan="1" colspan="1">Ferrous chlorophyllin (Fe&#8208;CHL) modified polylactic&#8208;co&#8208;glycolic acid NPs</td><td align="center" valign="top" rowspan="1" colspan="1">Melanoma cells in&#160;vitro (B16&#8208;F10)</td><td align="center" valign="top" rowspan="1" colspan="1">The nanobioconjugate showed enhanced cellular uptake of the PS and increased singlet oxygen yield</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0050" ref-type="bibr">50</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti&#8208;HER&#8208;2 antibodies (Ab)</td><td align="center" valign="top" rowspan="1" colspan="1">5&#8208;Aminolevulinic acid (5&#8208;ALA) conjugated to Gold&#8208;Silver NPs</td><td align="center" valign="top" rowspan="1" colspan="1">Breast cancer cells in&#160;vitro (MCF&#8208;7)</td><td align="center" valign="top" rowspan="1" colspan="1">The active nanocarrier system significantly reduced cell viability to 13% versus free PS with 49%</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0051" ref-type="bibr">51</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Folic acid</td><td align="center" valign="top" rowspan="1" colspan="1">Chlorin e6 loaded with thermosensitive liposomes (TSL) with copper sulfide (CuS) NPs</td><td align="center" valign="top" rowspan="1" colspan="1">Cervical cancer cells in&#160;vivo &amp; in&#160;vitro (HeLa)</td><td align="center" valign="top" rowspan="1" colspan="1">The active nanocarrier increased cellular uptake of Ce6 and controlled its release, which resulted in remarkable phototoxicity and inhibition of tumor growth</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0052" ref-type="bibr">52</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Transferrin</td><td align="center" valign="top" rowspan="1" colspan="1">Hypocrellin A (HA) loaded onto poly(<sc>d</sc>,<sc>l</sc>&#8208;Lactide&#8208;co&#8208;glycolide) (PLGA) &amp; carboxymethylchitosan (CMC) NPs</td><td align="center" valign="top" rowspan="1" colspan="1">Lung cancer cells in&#160;vitro &amp; vivo (A549)</td><td align="center" valign="top" rowspan="1" colspan="1">The nanobioconjugate induced apoptosis, which resulted in tumor delay at a 63% tumor inhibition rate for 15&#8201;days with negligible side effects on normal tissues</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0053" ref-type="bibr">53</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hyaluronic acid</td><td align="center" valign="top" rowspan="1" colspan="1">Chlorin e6 conjugated to &#946;&#8208;cholanic acid (5&#946;&#8208;CA) NPs</td><td align="center" valign="top" rowspan="1" colspan="1">Colon cancer cells in&#160;vitro &amp; in&#160;vivo (HT29)</td><td align="center" valign="top" rowspan="1" colspan="1">The nanobioconjugate&#8208;PDT considerably inhibited tumor growth by 10 fold versus control groups, which showed no alterations in tumor growth. In&#160;vivo tumor models presented no off&#8208;target toxicity</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0054" ref-type="bibr">54</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DNA Aptamer</td><td align="center" valign="top" rowspan="1" colspan="1">Chlorin e6 conjugated to gold NPs</td><td align="center" valign="top" rowspan="1" colspan="1">Liver cancer cells in&#160;vitro &amp; in&#160;vivo (HepG2)</td><td align="center" valign="top" rowspan="1" colspan="1">The nanobioconjugate demonstrated remarkable PDT and chemotherapeutic synergistic effects and showed improved cellular uptake</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0055" ref-type="bibr">55</xref>]</td></tr></tbody></table></table-wrap></sec><sec id="jbio70005-sec-0007"><label>2.5</label><title>Hypoxia Limitation in Photodynamic Therapy</title><p>Hypoxia is a common feature exhibited by solid tumors, which influences a series of physiological anomalies in the tumor microenvironment, including impaired tumor vasculature, erratic cellular proliferation, and a defective lymphatic system [<xref rid="jbio70005-bib-0056" ref-type="bibr">56</xref>, <xref rid="jbio70005-bib-0057" ref-type="bibr">57</xref>, <xref rid="jbio70005-bib-0058" ref-type="bibr">58</xref>]. In this instance, tumor cells generate energy through various metabolic pathways that are accelerated by consuming endogenous O<sub>2</sub>, particularly the oxidative phosphorylation (OXPHOS) metabolic pathway. As a result, the oxygen&#8208;dependent nature of PDT makes it difficult for ROS generation in tumor cells. Furthermore, this insufficient oxygen supply leads to limited ROS generated in a cell even after continuous PDT processes [<xref rid="jbio70005-bib-0059" ref-type="bibr">59</xref>, <xref rid="jbio70005-bib-0060" ref-type="bibr">60</xref>, <xref rid="jbio70005-bib-0061" ref-type="bibr">61</xref>]. Thus, at the cancer cell level (where PDT occurs), cancer cell characteristics (hypoxia) are not conducive to PDT (Figure&#160;<xref rid="jbio70005-fig-0003" ref-type="fig">3</xref>). When it comes to the PDT process (Figure&#160;<xref rid="jbio70005-fig-0003" ref-type="fig">3</xref>), oxygen consumption during PDT can worsen hypoxia in cancer cells and ultimately impede therapeutic outcomes by inducing changes in the proteome and genome of neoplastic cells. Nonetheless, anti&#8208;apoptotic factors get stimulated to attenuate the cytotoxic effects of PDT&#8208;generated ROS. In addition, tumor hypoxia promotes survival and tumor development by allowing cells to surmount nutrient scarcity or evade their hostile environment. Given this, tumor metastasis and angiogenesis are directly attributed to hypoxia and promote cellular proliferation, which significantly reduces the therapeutic effect of PDT. Therefore, tumor hypoxia counteracts PDT processes via ROS production and shields tumor cells from PDT&#8208;induced destruction by evoking a series of pro&#8208;survival reactions, ultimately promoting PDT resistance. In this regard, this poses a significant challenge in PDT [<xref rid="jbio70005-bib-0009" ref-type="bibr">9</xref>, <xref rid="jbio70005-bib-0062" ref-type="bibr">62</xref>].</p><fig position="float" fig-type="FIGURE" id="jbio70005-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Hypoxia activating signal transduction pathways linked to cell survival in cancer cells following photodynamic therapy [<xref rid="jbio70005-bib-0009" ref-type="bibr">9</xref>]. Copyright 2022, Elsevier.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="JBIO-18-e70005-g002.jpg"/></fig></sec><sec id="jbio70005-sec-0008"><label>2.6</label><title>Photoactivated Chemotherapy</title><p>The search for new chemotherapeutic drugs for cancer has been the main preoccupation of researchers for decades. As a result, transition metal&#8208;based agents have garnered significant attention, which is basically attributed to the long&#8208;term clinical application and foundation laid by cisplatin [<italic toggle="yes">cis</italic>&#8208;Pt (NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>] [<xref rid="jbio70005-bib-0063" ref-type="bibr">63</xref>, <xref rid="jbio70005-bib-0064" ref-type="bibr">64</xref>, <xref rid="jbio70005-bib-0065" ref-type="bibr">65</xref>, <xref rid="jbio70005-bib-0066" ref-type="bibr">66</xref>, <xref rid="jbio70005-bib-0067" ref-type="bibr">67</xref>, <xref rid="jbio70005-bib-0068" ref-type="bibr">68</xref>]. Cisplatin and its analogues (carboplatin, oxaliplatin, nedaplatin, heptaplatin, and lobaplatin) have yielded good results in the clinical treatment of various cancers [<xref rid="jbio70005-bib-0069" ref-type="bibr">69</xref>]. However, these cisplatin and its derivatives are hampered by poor target&#8208;specificity and off&#8208;target toxicity, which cause severe side effects such as hair loss, neuropathy, and myelotoxicity in patients [<xref rid="jbio70005-bib-0070" ref-type="bibr">70</xref>, <xref rid="jbio70005-bib-0071" ref-type="bibr">71</xref>, <xref rid="jbio70005-bib-0072" ref-type="bibr">72</xref>, <xref rid="jbio70005-bib-0073" ref-type="bibr">73</xref>]. Great strides have been made to address these issues, which include the incorporation of targeting nanocarrier systems and investigating reduction&#8208;responsive Pt(IV) prodrugs [<xref rid="jbio70005-bib-0074" ref-type="bibr">74</xref>, <xref rid="jbio70005-bib-0075" ref-type="bibr">75</xref>]. Furthermore, researchers are actively engaged in developing photoactivated Pt(IV) agents, which are inactive in the dark but can release tumoricidal Pt(II) species upon exposure to light irradiation. These prodrugs are referred to as PACT agents, which allow for controlled timing and location of radiation exposure to confined drug activity within tumor tissues with negligible side effects on normal tissues [<xref rid="jbio70005-bib-0015" ref-type="bibr">15</xref>, <xref rid="jbio70005-bib-0018" ref-type="bibr">18</xref>, <xref rid="jbio70005-bib-0076" ref-type="bibr">76</xref>].</p><p>PACT is oxygen&#8208;independent, which makes it suitable for treating hypoxic tumors [<xref rid="jbio70005-bib-0077" ref-type="bibr">77</xref>, <xref rid="jbio70005-bib-0078" ref-type="bibr">78</xref>]. In contrast, the efficacy of PDT mainly hinges on the availability of tumor molecular oxygen. However, tumor masses are deprived of oxygen due to their uncontrolled growth and suboptimal vascularization, as well as increased distances for oxygen diffusion [<xref rid="jbio70005-bib-0077" ref-type="bibr">77</xref>]. PACT holds great promise to circumvent this limitation [<xref rid="jbio70005-bib-0018" ref-type="bibr">18</xref>]. The tremendous potency exhibited by Pt complexes in cancer therapy has propelled the investigation of other transition metal complexes, in particular Ruthenium (Ru) complexes, due to their potential tumoricidal properties and high affinity for cancer cells [<xref rid="jbio70005-bib-0079" ref-type="bibr">79</xref>]. Researchers in modern medicinal inorganic chemistry are now focused on developing new Ru&#8208;based [<xref rid="jbio70005-bib-0080" ref-type="bibr">80</xref>, <xref rid="jbio70005-bib-0081" ref-type="bibr">81</xref>, <xref rid="jbio70005-bib-0082" ref-type="bibr">82</xref>, <xref rid="jbio70005-bib-0083" ref-type="bibr">83</xref>]. Several Ru(III) complexes, such as NAMI&#8208;A, KP1019, and KP1339, have reached the clinical trial stage thus far [<xref rid="jbio70005-bib-0084" ref-type="bibr">84</xref>, <xref rid="jbio70005-bib-0085" ref-type="bibr">85</xref>, <xref rid="jbio70005-bib-0086" ref-type="bibr">86</xref>, <xref rid="jbio70005-bib-0087" ref-type="bibr">87</xref>, <xref rid="jbio70005-bib-0088" ref-type="bibr">88</xref>]. Being the first Ru complex authorized for use in clinical trials, NAMI&#8208;A demonstrated improved efficacy in phase I trials but unfavorable outcomes in phase II, which led to the failure of clinical trials [<xref rid="jbio70005-bib-0081" ref-type="bibr">81</xref>, <xref rid="jbio70005-bib-0089" ref-type="bibr">89</xref>]. One study investigated NAMI&#8208;A in humans in phase I trials [<xref rid="jbio70005-bib-0088" ref-type="bibr">88</xref>]. The study entailed 12 dose levels (2.4&#8211;500&#8201;mg/m<sup>2</sup>/day). Twenty&#8208;four adult patients diagnosed with different types of solid tumors, were treated with NAMI&#8208;A (3&#8201;h) for five consecutive days every 3&#8201;weeks. The side effects of NAMI&#8208;A were less severe compared to platinum anticancer drugs: moderate renal toxicity, which was noted at the highest doses, was completely reversible, whereas hematological toxicity was minimal. Doses &#8805;&#8201;400&#8201;mg/m<sup>2</sup>/day caused painful blisters on fingers and toes. The maximum tolerated dose (MTD) of 300&#8201;mg/m<sup>2</sup>/day resulted in treatable mild to moderate general malaise, nausea, vomiting, and diarrhea. Due to its high affinity for blood proteins, ruthenium's total body retention was greater than predicted from preclinical studies [<xref rid="jbio70005-bib-0090" ref-type="bibr">90</xref>].</p><p>A study (2008&#8211;2011) conducted on 32 patients with advanced Non&#8208;small cell lung cancer (NSCLC) [<xref rid="jbio70005-bib-0089" ref-type="bibr">89</xref>]. Gemcitabine was administered at a typical dose of 1&#8201;g/m<sup>2</sup> on, whereas dose escalation of NAMI&#8208;A was administered intravenously (3&#8201;h) on days 1 and 8 of a 3&#8208;week&#8201;cycle&#8212;was performed in phase I of the study. CTC (common terminology criteria) grade 2&#8211;4 neutropenia and anemia were reported at the highest doses, whereas the already mentioned blisters (dose&#8208;limiting toxicity) were observed at 600&#8201;mg/m<sup>2</sup>. The MTD was found to be 450&#8201;mg/m<sup>2</sup>, where the main non&#8208;hematological adverse events were elevated liver enzymes, transient creatinine elevation, renal toxicity, constipation, and fatigue. In phase II of the study, the antitumor activity determined by RECIST (response evaluation criteria in solid tumors) criteria for solid tumors [<xref rid="jbio70005-bib-0091" ref-type="bibr">91</xref>] was evaluated on 15 patients treated with the MTD of NAMI&#8208;A.</p><p>The expansion of the phase II cohort with additional patients was not undertaken due to the treatment's efficacy being lower than anticipated for gemcitabine alone, resulting in one case of partial remission and 10 patients exhibiting stable disease for a duration of 6&#8211;8&#8201;weeks. Furthermore, the patients found the combination treatment to be very exhausting, primarily because of the severe nausea, vomiting, and diarrhea [<xref rid="jbio70005-bib-0089" ref-type="bibr">89</xref>].</p><p>Subsequently, another Ru chemotherapeutic, KP1019, showed poor water compatibility in phase I, which is now superseded by a more soluble sodium salt, KP1339, currently explored in clinical trials [<xref rid="jbio70005-bib-0081" ref-type="bibr">81</xref>]. In 2006, a preliminary phase I dose&#8208;escalation study was conducted with KP1019 (25&#8211;600&#8201;mg) on only eight patients diagnosed with advanced solid tumors [<xref rid="jbio70005-bib-0087" ref-type="bibr">87</xref>, <xref rid="jbio70005-bib-0092" ref-type="bibr">92</xref>]. The complex was administered intravenously two times a week for 3&#8201;weeks and showed mild toxicity with the investigated dose range. The condition of five out of six examined patients remained stable, which was unrelated to the dose. Due to poor solubility (too large a volume of infusion solution needed for further dose escalation), the MTD of KP1019 could not be established, which resulted in a full&#8208;scale phase I study conducted on 34 patients using a more soluble sodium derivative Na[<italic toggle="yes">trans</italic>&#8208;RuCl<sub>4</sub>(Ind)<sub>2</sub>] (KP1339/IT&#8208;139). The study used nine dose levels (20&#8211;780&#8201;mg/m<sup>2</sup>/day), and the complex was administered intravenously on days 1, 8, and 15 in a 28&#8208;day&#8201;cycle [<xref rid="jbio70005-bib-0093" ref-type="bibr">93</xref>]. The treatment caused negligible side effects. Grade 2&#8211;3 nausea accompanied by elevated levels of creatinine was found to be DLT (dose&#8208;limiting toxicity) at the maximum dose. Seven patients with various types of tumors (including two cases of NSCLC) remained stable for up to 88&#8201;weeks, and one patient with a neuroendocrine tumor exhibited a partial response (PR).</p><p>Years later, Burris et&#160;al., 2016 conducted another phase I clinical trial on 46 patients, with the same dose levels and treatment schedule. The MTD was found to be 625&#8201;mg/m<sup>2</sup> [<xref rid="jbio70005-bib-0094" ref-type="bibr">94</xref>, <xref rid="jbio70005-bib-0095" ref-type="bibr">95</xref>]. Similarly, the tolerability and safety profile showed no significant hematological toxicity or neurotoxicity, the main adverse events being clinically manageable grade &#8804;&#8201;2 nausea, fatigue, and vomiting. Overall, the complex resulted in moderate antitumor activity, with 26% disease control efficacy in three of the five patients with carcinoid neuroendocrine tumors, and one PR was observed in a patient with colon cancer.</p><p>In recent years, more focus has shifted from the chemotherapeutic activity of Ru(III) complexes to the phototoxic effects of Ru(II) complexes. The first Ru(II)&#8208;based PS for PDT applications, TLD1433, has been approved for human clinical trials (Figure&#160;<xref rid="jbio70005-fig-0004" ref-type="fig">4</xref>) [<xref rid="jbio70005-bib-0096" ref-type="bibr">96</xref>]. Furthermore, studies have also pointed out that Ru(II) complexes have the potential to serve as PACT agents (Figure&#160;<xref rid="jbio70005-fig-0004" ref-type="fig">4</xref>) [<xref rid="jbio70005-bib-0097" ref-type="bibr">97</xref>, <xref rid="jbio70005-bib-0098" ref-type="bibr">98</xref>, <xref rid="jbio70005-bib-0099" ref-type="bibr">99</xref>, <xref rid="jbio70005-bib-0100" ref-type="bibr">100</xref>]. They are capable of photoinduced ligand dissociation through appropriate structural design, and the resulting Ru(II) aqua species can covalently bind to DNA in a way that is comparable to cisplatin. Ru(II)&#8208;based PACT agents show some prospective advantages over Pt(IV) complexes. They have extensive photophysical and photochemical capabilities, a variety of easily modifiable structures, and potentially high efficacy against cisplatin&#8208;resistant cancer cells due to their octahedral structures, which differ from those of cisplatin [<xref rid="jbio70005-bib-0071" ref-type="bibr">71</xref>, <xref rid="jbio70005-bib-0101" ref-type="bibr">101</xref>, <xref rid="jbio70005-bib-0102" ref-type="bibr">102</xref>]. Ru(II) complexes typically exhibit the lowest energy absorption band due to <sup>1</sup>MLCT (Metal&#8208;to&#8208;Ligand Charge Transfer) transitions [<xref rid="jbio70005-bib-0076" ref-type="bibr">76</xref>, <xref rid="jbio70005-bib-0103" ref-type="bibr">103</xref>]. When exposed to suitable light, Ru(II) complexes transition from the <sup>1</sup>MLCT state to the <sup>3</sup>MLCT state via rapid intersystem crossing (Figure&#160;<xref rid="jbio70005-fig-0005" ref-type="fig">5</xref>). This results in the dissociation and generation of Ru(II) aqua species, which have a high DNA&#8208;binding affinity, showing potential in PACT therapeutic effects [<xref rid="jbio70005-bib-0076" ref-type="bibr">76</xref>].</p><fig position="float" fig-type="FIGURE" id="jbio70005-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Ruthenium metallodrugs explored in clinical trials [<xref rid="jbio70005-bib-0104" ref-type="bibr">104</xref>]. Copyright 2025, Elsevier.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="JBIO-18-e70005-g007.jpg"/></fig><fig position="float" fig-type="FIGURE" id="jbio70005-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Jablonski diagram of Ru(II) complexes with photolabile ligands.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="JBIO-18-e70005-g006.jpg"/></fig></sec><sec id="jbio70005-sec-0009"><label>2.7</label><title>Prodrugs Outcomes in Cancer Therapy</title><p>Studies by van Geest et&#160;al. [<xref rid="jbio70005-bib-0011" ref-type="bibr">11</xref>] developed a ruthenium&#8208;based complex capable of revealing itself after cellular uptake. This prodrug was embedded in liposomes and showed no dark toxicity in human skin melanoma cells (A375). Upon light irradiation, this prodrug destroyed cancer cells by releasing STF&#8208;31, a cytotoxic nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, as well as cytotoxic singlet oxygen [<xref rid="jbio70005-bib-0011" ref-type="bibr">11</xref>].</p><p>In another study, Elias and colleagues [<xref rid="jbio70005-bib-0010" ref-type="bibr">10</xref>] investigated the anticancer effects of the Ru complex, [Ru(bpy)<sub>2</sub>BC]Cl<sub>2</sub> on melanoma cells. Elias et&#160;al. revealed that cell viability results showed a mean phototoxicity index of 340&#8208;fold, which was attributed to aquated photoproducts rather than dissociating ligands. In addition, a significant increase in ROS yield and DNA damage was also observed. Elias and colleagues noted an increase in the early apoptotic cell population at 48&#8201;h, which proceeded to the late apoptotic/necrotic cell population at 72&#8201;h. On further analysis, western blot results revealed that pro&#8208; and anti&#8208;apoptotic proteins were facilitated by an interplay between the intrinsic and extrinsic pathways, as well as autophagy and via attenuation of the MAPK and PI3K pathways. Therefore, this study proved that [Ru(bpy)<sub>2</sub>BC]Cl<sub>2</sub> is a diverse PACT drug endowed with promising anticancer potential.</p><p>Boerhan et&#160;al. [<xref rid="jbio70005-bib-0105" ref-type="bibr">105</xref>] investigated the phototoxicity of three fluorinated dppz ligand&#8208;coordinated Ru(II) complexes (<bold>2&#8211;4</bold>) containing four monodentate pyridine ligands. These complexes released one pyridine and were covalently bound to DNA after exposure to 470&#8201;nm laser irradiation. Boerhan and colleagues complexed noted that compared to the parent complex [Ru(dppz)(py)<sub>4</sub>]<sup>2+</sup> (<bold>1</bold>), <bold>2&#8211;4</bold> exhibited improved phototoxic effects but negligible dark cytotoxicity, making them more ideal for PACT application. Complex <bold>3</bold> showed was the most efficient with IC<sub>50</sub> values of about 8&#8201;&#956;M toward HeLa and SKOV&#8208;3 cell lines and also had a much greater IC<sub>50</sub> value toward normal L&#8208;02 cells. Recent studies conducted by Dao et&#160;al. [<xref rid="jbio70005-bib-0016" ref-type="bibr">16</xref>] investigated the antitumor efficacy of Ru(II) complex (<bold>Ru2</bold>) on 4T1 cancer cells. Dao and colleagues noted that with the addition of a donor&#8208;acceptor&#8208;donor (D&#8208;A&#8208;D) linker, the intramolecular charge transition was significantly improved, leading to a high molar extinction coefficient and a long triplet excited state lifespan in the near&#8208;infrared spectrum. Interestingly, <bold>Ru2</bold> demonstrated distinct slow photodissociation kinetics upon activation by 700&#8201;nm NIR light, which enable cooperative photosensitization and photocatalytic activity to degrade various intracellular biomolecules. In&#160;vitro and in&#160;vivo studies demonstrated that the exposure of <bold>Ru2</bold> to 700&#8201;nm NIR light caused nanomolar photocytotoxicity on 4T1 cancer cells through the induction of calcium overload and endoplasmic reticulum (ER) stress.</p><p>Sun et&#160;al. [<xref rid="jbio70005-bib-0106" ref-type="bibr">106</xref>] designed a novel phototoxic Ru&#8208;containing block copolymer. The polymer was composed of a hydrophobic Ru&#8208;containing block and a hydrophilic poly(ethylene glycol) block that contains drug&#8208;Ru complex conjugates that are red&#160;light cleavable (650&#8211;680&#8201;nm). The block copolymer was encapsulated in micelles to efficiently enhance its bioavailability in cancer cells. Red light initiated the release of the drug&#8208;Ru complex nanoformulation from the micelles, and inhibited tumor growth even in a hypoxic tumor environment. Furthermore, no off&#8208;target toxicity was observed in mice treated with this nanoformulation, indicative of the system's excellent biocompatibility with healthy tissues and blood. Sun et&#160;al. [<xref rid="jbio70005-bib-0088" ref-type="bibr">88</xref>] concluded that this novel red&#8208;light&#8208;responsive Ru&#8208;containing polymer paves new avenues for phototherapy against hypoxic tumors. Mari et&#160;al. [<xref rid="jbio70005-bib-0098" ref-type="bibr">98</xref>] incorporated Ru<sup>II</sup>&#8208;polypyridyl complexes with a peptide carrier (bombesin), which has a high affinity for receptors overexpressed by the&#160;cell membrane of HeLa cells. As anticipated, this peptide&#160;showed a high affinity for HeLa cells compared with normal MRC&#8208;5 cells. As a result, no cytotoxicity was observed&#160;in normal cells, while a significant phototoxicity was observed in HeLa cells upon irradiation. Table&#160;<xref rid="jbio70005-tbl-0004" ref-type="table">4</xref> summarizes prodrugs that have shown promising results in PACT applications.</p><table-wrap position="float" id="jbio70005-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Summary of prodrugs studies in cancer therapy.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Prodrugs</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cancer</th><th align="center" valign="bottom" rowspan="1" colspan="1">Wavelength (nm)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Outcomes</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">[Ru(3)(biq)(STF&#8208;31)](PF<sub>6</sub>)<sub>2</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">A375 human skin melanoma cells in&#160;vitro</td><td align="center" valign="top" rowspan="1" colspan="1">520</td><td align="center" valign="top" rowspan="1" colspan="1">The prodrug encapsulated in liposomes showed increased cellular uptake and significant anti&#8208;proliferative effects on cancer cells when compared to free</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0011" ref-type="bibr">11</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ru&#8208;STF31</td><td align="center" valign="top" rowspan="1" colspan="1">Glioblastoma cancer cell line, U87MG in&#160;vitro</td><td align="center" valign="top" rowspan="1" colspan="1">630</td><td align="center" valign="top" rowspan="1" colspan="1">Ru&#8208;STF31 exhibited increased phototoxicity in normoxic and hypoxic U87MG cells</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0107" ref-type="bibr">107</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ru polypyridyl complexes</td><td align="center" valign="top" rowspan="1" colspan="1">H23 (breast cancer) and T47D (lung cancer) cell lines in&#160;vitro</td><td align="center" valign="top" rowspan="1" colspan="1">450</td><td align="center" valign="top" rowspan="1" colspan="1">Ru complexes exhibited cytotoxicity in cancer cells</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0108" ref-type="bibr">108</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">[Ru(bipy)<sub>2</sub>(dpphen)]Cl<sub>2</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">A549 (lung) cancer cells in&#160;vitro</td><td align="center" valign="top" rowspan="1" colspan="1">460</td><td align="center" valign="top" rowspan="1" colspan="1">Ru prodrug showed potent anticancer effects against A549 cells, which resulted in cell rounding and detachment, loss of membrane integrity, and DNA damage, representing apoptosis</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0109" ref-type="bibr">109</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ru(7&#8208;OCH<sub>3</sub>&#8208;dppz)(4&#8208;OCH<sub>3</sub>&#8208;py)<sub>4</sub>(PF<sub>6</sub>)<sub>2</sub> (Ru1)</td><td align="center" valign="top" rowspan="1" colspan="1">Cisplatin&#8208;resistant A549 (lung) 3&#8208;D multicellular tumor spheroids</td><td align="center" valign="top" rowspan="1" colspan="1">800</td><td align="center" valign="top" rowspan="1" colspan="1">Ru conjugated to NPs showed more efficient PACT activity towards 3&#8208;D&#8208;cultured cancer cells under both normoxic and hypoxic conditions versus free Ru</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0110" ref-type="bibr">110</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">[Ru(&#951;<sup>6</sup>&#8208;<italic toggle="yes">p</italic>&#8208;cymene)pta&#8208;(N<sub>3</sub>)<sub>2</sub>]</td><td align="center" valign="top" rowspan="1" colspan="1">Human cervical carcinoma (HeLa)</td><td align="center" valign="top" rowspan="1" colspan="1">450</td><td align="center" valign="top" rowspan="1" colspan="1">Ru complex revealed a modest cytotoxicity in the dark, which drastically increased upon exposure to light</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="jbio70005-bib-0111" ref-type="bibr">111</xref>]</td></tr></tbody></table></table-wrap></sec><sec id="jbio70005-sec-0010"><label>2.8</label><title>The Combined Effect of Photodynamic Therapy and Photoactivated Chemotherapy on Solid Tumors</title><p>The combinatorial approach of PDT and PACTS is a promising and novel synergistic strategy for improving cancer treatment outcomes. By leveraging the efficacy of both light&#8208;based therapies, this approach holds great promise for circumventing hurdles faced by conventional therapies, allowing for more efficient and target&#8208;specific cancer therapy [<xref rid="jbio70005-bib-0112" ref-type="bibr">112</xref>]. PDT, which relies on light to excite a photoactivable molecule that induces cell death due to the production of ROS, is effective at selectively targeting tumor cells but can be hampered by the hypoxic tumor environment Figure&#160;<xref rid="jbio70005-fig-0006" ref-type="fig">6</xref> [<xref rid="jbio70005-bib-0009" ref-type="bibr">9</xref>].</p><fig position="float" fig-type="FIGURE" id="jbio70005-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>The hypoxic tumor region is farther away from feeding vessels, which play a key role in tumor resistance to photodynamic therapy.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="JBIO-18-e70005-g004.jpg"/></fig><p>A longstanding obstacle of cancer therapies, including PDT and PACT, is related to the poor bioavailability of PSs and prodrugs in tumor tissues, reducing the complete diffusion of these photoactive molecules throughout the tumor. This may significantly diminish the number of active molecules in the targeted tumor regions as well as in various layers of the tumor, resulting in incomplete tumor elimination [<xref rid="jbio70005-bib-0113" ref-type="bibr">113</xref>, <xref rid="jbio70005-bib-0114" ref-type="bibr">114</xref>]. Moreover, unfavorable biodistribution may result in prolonged periods of unwanted retention in healthy tissues. To address this issue, researchers are actively engaged in improving the targeting specificity of PS and prodrugs to reduce their off&#8208;target accumulation as well as enhance their overall therapeutic efficacy [<xref rid="jbio70005-bib-0007" ref-type="bibr">7</xref>, <xref rid="jbio70005-bib-0113" ref-type="bibr">113</xref>]. This is attained by incorporating smart delivery systems, such as antibodies, liposomes, and NPs, that may promote excellent biodistribution [<xref rid="jbio70005-bib-0115" ref-type="bibr">115</xref>]. The encapsulation or incorporation with smart delivery systems confers to some extent control in the distribution of the PS/prodrug&#8208;carrier complex.</p><p>In order to treat deep&#8208;seated cancers and evade melanin absorption, a variety of strategies have been used in recent years to overcome cancer resistance to phototherapeutic modalities. One such strategy is the use of photoactive molecules excited by light in the far&#8208;red and near&#8208;infrared ranges. Melanin typically scatters and absorbs throughout the 400&#8211;700&#8201;nm spectral range that is utilized in PDT [<xref rid="jbio70005-bib-0116" ref-type="bibr">116</xref>]. Most clinically approved PS absorb below 700&#8201;nm, calling for the need for developing new PSs that absorb in the NIR region, such as bacteriochlorins and Si(IV)&#8208;naphthalocyanine. Bussetti et&#160;al. [<xref rid="jbio70005-bib-0117" ref-type="bibr">117</xref>] reported that photoactivated Si(IV)&#8208;naphthalocyanine with a 1064&#8201;nm laser at 520&#8201;J/cm<sup>2</sup> resulted in a significant 16&#8208;day delay of tumor growth. In another study by Mroz et&#160;al. [<xref rid="jbio70005-bib-0118" ref-type="bibr">118</xref>], it was reported that 1&#8201;&#956;M bacteriochlorin and a 730&#8201;nm laser at 120&#8201;J/cm<sup>2</sup> significantly inhibited the cell viability of B16F10 cells by 98%. Another approached used to overcome melanin absorbance and reach deep&#8208;rooted tumors is through the functionalization of PSs and prodrugs with NPs that have a strong absorption in the NIR region, such as upconversion and mesoporous silica NPs [<xref rid="jbio70005-bib-0117" ref-type="bibr">117</xref>, <xref rid="jbio70005-bib-0118" ref-type="bibr">118</xref>]. Lee et&#160;al. [<xref rid="jbio70005-bib-0119" ref-type="bibr">119</xref>] functionalized indocyanine green (ICG) with chitosan&#8208;coated liposomes to significantly augment cellular uptake and photocytotoxicity of ICG in B16&#8208;F10 melanoma cells. Lee and colleagues noted the nanoformulation enhanced skin permeation of ICG, and 40&#8201;&#956;M ICG&#8208;chitosan&#8208;coated liposomes, and a 785&#8201;nm laser at a power intensity of 100&#8201;mW/cm<sup>2</sup> showed a significant increase in the inhibitory effect when compared to free ICG. Ru(II)&#8208;based PACT agents are effective in treating cancer, but their limited in&#160;vivo uses stem from their short wavelength absorption (usually less than 550&#8201;nm) and undesirable tumor accumulation.</p><p>Zhang et&#160;al. [<xref rid="jbio70005-bib-0120" ref-type="bibr">120</xref>] modified Ru(II)&#8208;based PACT agent with bovine serum albumin (BSA) attached on the surface of lanthanide&#8208;doped upconversion NPs (UCNP@BSA@Ru) to improve Ru(II) cellular uptake and target&#8208;selectivity in tumor cells. Zhang and colleagues revealed that the nanobioconjugate showed a highly effective and selective affinity for tumor cells in&#160;vitro and in&#160;vivo due to the targeting abilities of BSA and the EPR effect conferred by NPs. Following light irradiation at 980&#8201;nm, the nanobioconjugate significantly exerted cytotoxic effects in cancer with negligible effects on the normal IOSE80 cells. Furthermore, in&#160;vivo results showed that the nanobioconjugate significantly inhibited tumor growth after photoactivation using 980&#8201;nm. Therefore, dual delivery of PSs and prodrugs both encapsulated into nanoparticles functionalized with targeting moieties (e.g., antibodies, folic acid, and peptides) could selectively target cancer while minimizing damage to normal tissues and exerting PDT&#8208;PACT synergistic cytotoxic effects that prevent tumor resistance. Furthermore, the modification of PSs and prodrugs with NPs that absorb light within the NIR region could not only allow for the treatment of deep&#8208;seated tumors but also evade light absorption by endogenous chromophores such as hemoglobin, myoglobin, and cytochrome or melanin [<xref rid="jbio70005-bib-0005" ref-type="bibr">5</xref>], which counteract the PDT&#8208;PACT processes by competing with PS and prodrugs in the absorption process.</p></sec></sec><sec sec-type="conclusions" id="jbio70005-sec-0011"><label>3</label><title>Conclusion</title><p>The combination of PACT and active&#8208;targeted PDT represents a novel and promising approach to enhancing cancer prognosis in patients. Despite PDT showing great potential as a minimally invasive treatment modality, its therapeutic efficacy is often hampered by the hypoxic tumor microenvironment and limitations of traditional PSs. Similarly, PACT provides a controlled and localized chemotherapeutic effect, though it faces challenges related to solubility, target selectivity, and systemic toxicity [<xref rid="jbio70005-bib-0107" ref-type="bibr">107</xref>, <xref rid="jbio70005-bib-0110" ref-type="bibr">110</xref>]. The combination of these two modalities allows for a synergistic cytotoxic effect, enhancing selectivity, reducing side effects, and attenuating tumor&#8208;resistant mechanisms.</p><p>Recent advances in nanotechnology have paved new avenues for enhancing the efficacy of PDT and PACT. Nanocarrier&#8208;mediated drug delivery platforms have significantly improved PS and prodrug bioavailability, target selectivity, and therapeutic effect [<xref rid="jbio70005-bib-0007" ref-type="bibr">7</xref>]. Functionalized NPs can selectively accumulate in targeted tumor regions, improve cellular uptake, and control drug release, thereby mitigating off&#8208;target toxicity and improving treatment specificity [<xref rid="jbio70005-bib-0031" ref-type="bibr">31</xref>]. Furthermore, the introduction of near&#8208;infrared (NIR) light&#8208;responsive nanomaterials holds great promise in the therapy of deep&#8208;seated tumors and therefore broadens the clinical utility of this synergy approach [<xref rid="jbio70005-bib-0114" ref-type="bibr">114</xref>].</p><p>Despite these advances, there is still a significant research gap concerning the co&#8208;delivery of PSs and prodrugs using an active&#8208;targeted nanocarrier platform. More research is needed to optimize the formation of delivery efficiency and clinical translational potential of such systems. Future directives include refining the design of multifunctional nanocarriers, discovering new PS&#8208;prodrug combinations, and conducting extensive preclinical and clinical trials to determine the full potential of PDT&#8208;PACT synergy in cancer [<xref rid="jbio70005-bib-0121" ref-type="bibr">121</xref>].</p><p>The overall findings from this study suggest that there are currently no studies that have investigated the combination therapy in relation to the active&#8208;targeted nanocarrier platforms incorporating PDT and PACT to prevent drug resistance and improve the overall treatment outcomes. Thus, this study warrants further investigations of active&#8208;targeted nanocarrier systems for dual delivery of PSs and prodrugs.</p></sec><sec id="jbio70005-sec-0012"><title>Author Contributions</title><p>Conceptualization: N.W.N. and H.A. Writing &#8211; original draft preparation: N.W.N. Writing &#8211; review and editing: H.A. Supervision: H.A. All authors have read and agreed to the published version of the manuscript.</p></sec><sec sec-type="COI-statement" id="jbio70005-sec-0013"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><sec sec-type="data-availability" id="jbio70005-sec-0015"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="jbio70005-bibl-0001"><title>References</title><ref id="jbio70005-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jbio70005-cit-0001"><string-name name-style="western"><given-names>O.</given-names><surname>Obidiro</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Battogtokh</surname></string-name>, and <string-name name-style="western"><given-names>E. O.</given-names><surname>Akala</surname></string-name>, &#8220;<article-title>Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook</article-title>,&#8221; <source>Pharmaceutics</source><volume>15</volume>, no. <issue>7</issue> (<year>2023</year>): <elocation-id>1796</elocation-id>, <pub-id pub-id-type="doi">10.3390/pharmaceutics15071796</pub-id>.<pub-id pub-id-type="pmid">37513983</pub-id><pub-id pub-id-type="pmcid">PMC10384267</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jbio70005-cit-0002"><string-name name-style="western"><given-names>S. B.</given-names><surname>Mali</surname></string-name>, &#8220;<article-title>Cancer Treatment: Role of Natural Products. Time to Have a Serious Rethink</article-title>,&#8221; <source>Oral Oncology Reports</source><volume>6</volume> (<year>2023</year>): <elocation-id>100040</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.oor.2023.100040</pub-id>.</mixed-citation></ref><ref id="jbio70005-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jbio70005-cit-0003"><string-name name-style="western"><given-names>C.</given-names><surname>Tang</surname></string-name> and <string-name name-style="western"><given-names>H.</given-names><surname>Li</surname></string-name>, &#8220;<article-title>Application of Nanoparticles in the Early Diagnosis and Treatment of Tumours: Current Status and Progress</article-title>,&#8221; <source>Traditional Medicine Research</source><volume>5</volume> (<year>2020</year>): <fpage>34</fpage>&#8211;<lpage>43</lpage>, <pub-id pub-id-type="doi">10.12032/TMR20191228152</pub-id>.</mixed-citation></ref><ref id="jbio70005-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jbio70005-cit-0004"><string-name name-style="western"><given-names>C.&#8208;N.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Hsu</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Chen</surname></string-name>, and <string-name name-style="western"><given-names>T.&#8208;W.</given-names><surname>Wong</surname></string-name>, &#8220;<article-title>Daylight Photodynamic Therapy: An Update</article-title>,&#8221; <source>Molecules</source><volume>25</volume> (<year>2020</year>): <elocation-id>5195</elocation-id>, <pub-id pub-id-type="doi">10.3390/molecules25215195</pub-id>.<pub-id pub-id-type="pmid">33171665</pub-id><pub-id pub-id-type="pmcid">PMC7664668</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jbio70005-cit-0005"><string-name name-style="western"><given-names>J. H.</given-names><surname>Correia</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Rodrigues</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Pimenta</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Dong</surname></string-name>, and <string-name name-style="western"><given-names>Z.</given-names><surname>Yang</surname></string-name>, &#8220;<article-title>Photodynamic Therapy Review: Principles, Photosensitizers, Applications, and Future Directions</article-title>,&#8221; <source>Pharmaceutics</source><volume>13</volume> (<year>2021</year>): <elocation-id>1332</elocation-id>, <pub-id pub-id-type="doi">10.3390/pharmaceutics13091332</pub-id>.<pub-id pub-id-type="pmid">34575408</pub-id><pub-id pub-id-type="pmcid">PMC8470722</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jbio70005-cit-0006"><string-name name-style="western"><given-names>L.</given-names><surname>Shang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Shi</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Zhong</surname></string-name>, &#8220;<article-title>Metal Nanoparticles for Photodynamic Therapy: A Potential Treatment for Breast Cancer</article-title>,&#8221; <source>Molecules</source><volume>26</volume> (<year>2021</year>): <elocation-id>6532</elocation-id>, <pub-id pub-id-type="doi">10.3390/molecules26216532</pub-id>.<pub-id pub-id-type="pmid">34770941</pub-id><pub-id pub-id-type="pmcid">PMC8588551</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jbio70005-cit-0007"><string-name name-style="western"><given-names>S.</given-names><surname>Kwiatkowski</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Knap</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Przystupski</surname></string-name>, et&#160;al., &#8220;<article-title>Photodynamic Therapy&#8212;Mechanisms, Photosensitizers and Combinations</article-title>,&#8221; <source>Biomedicine &amp; Pharmacotherapy</source><volume>106</volume> (<year>2018</year>): <fpage>1098</fpage>&#8211;<lpage>1107</lpage>, <pub-id pub-id-type="doi">10.1016/j.biopha.2018.07.049</pub-id>.<pub-id pub-id-type="pmid">30119176</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jbio70005-cit-0008"><string-name name-style="western"><given-names>W.</given-names><surname>Yan</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Lang</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Zhu</surname></string-name>, et&#160;al., &#8220;<article-title>Anti&#8208;Hypoxia Nanosized Drug Delivery Systems Improving Cancer Therapy</article-title>,&#8221; <source>Nano Today</source><volume>42</volume> (<year>2022</year>): <elocation-id>101376</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.nantod.2022.101376</pub-id>.</mixed-citation></ref><ref id="jbio70005-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jbio70005-cit-0009"><string-name name-style="western"><given-names>R.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zeng</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Chen</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Wu</surname></string-name>, &#8220;<article-title>Combating the Hypoxia Limit of Photodynamic Therapy Through Reversing the Survival&#8208;Related Pathways of Cancer Cells</article-title>,&#8221; <source>Coordination Chemistry Reviews</source><volume>452</volume> (<year>2022</year>): <elocation-id>214306</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.ccr.2021.214306</pub-id>.</mixed-citation></ref><ref id="jbio70005-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jbio70005-cit-0010"><string-name name-style="western"><given-names>M. G.</given-names><surname>Elias</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Mehanna</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Elias</surname></string-name>, <string-name name-style="western"><given-names>R. S.</given-names><surname>Khnayzer</surname></string-name>, and <string-name name-style="western"><given-names>C. F.</given-names><surname>Daher</surname></string-name>, &#8220;<article-title>A Photoactivatable Chemotherapeutic Ru(II) Complex Bearing Bathocuproine Ligand Efficiently Induces Cell Death in Human Malignant Melanoma Cells Through a Multi&#8208;Mechanistic Pathway</article-title>,&#8221; <source>Chemico&#8208;Biological Interactions</source><volume>348</volume> (<year>2021</year>): <elocation-id>109644</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.cbi.2021.109644</pub-id>.<pub-id pub-id-type="pmid">34508709</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jbio70005-cit-0011"><string-name name-style="western"><given-names>E. P.</given-names><surname>van Geest</surname></string-name>, <string-name name-style="western"><given-names>S. K.</given-names><surname>G&#246;tzfried</surname></string-name>, <string-name name-style="western"><given-names>D. M.</given-names><surname>Klein</surname></string-name>, et&#160;al., &#8220;<article-title>A Lock&#8208;and&#8208;Kill Anticancer Photoactivated Chemotherapy Agent</article-title>,&#8221; <source>Photochemistry and Photobiology</source><volume>99</volume> (<year>2023</year>): <fpage>777</fpage>&#8211;<lpage>786</lpage>, <pub-id pub-id-type="doi">10.1111/php.13738</pub-id>.<pub-id pub-id-type="pmid">36315051</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jbio70005-cit-0012"><string-name name-style="western"><given-names>M.</given-names><surname>Wainwright</surname></string-name>, &#8220;<article-title>Photodynamic Antimicrobial Chemotherapy (PACT)</article-title>,&#8221; <source>Journal of Antimicrobial Chemotherapy</source><volume>42</volume> (<year>1998</year>): <fpage>13</fpage>&#8211;<lpage>28</lpage>, <pub-id pub-id-type="doi">10.1093/jac/42.1.13</pub-id>.<pub-id pub-id-type="pmid">9700525</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jbio70005-cit-0013"><string-name name-style="western"><given-names>K. M.</given-names><surname>Kuznetsov</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Cariou</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Gasser</surname></string-name>, &#8220;<article-title>Two in One: Merging Photoactivated Chemotherapy and Photodynamic Therapy to Fight Cancer</article-title>,&#8221; <source>Chemical Science</source><volume>15</volume> (<year>2024</year>): <fpage>17760</fpage>&#8211;<lpage>17780</lpage>, <pub-id pub-id-type="doi">10.1039/D4SC04608K</pub-id>.<pub-id pub-id-type="pmid">39464604</pub-id><pub-id pub-id-type="pmcid">PMC11499979</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jbio70005-cit-0014"><string-name name-style="western"><given-names>V.</given-names><surname>Ramu</surname></string-name>, <string-name name-style="western"><given-names>A. B.</given-names><surname>Auyeung</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Bonnet</surname></string-name>, &#8220;<article-title>Cytotoxicity of Metal&#8208;Based Photoactivated Chemotherapy (PACT) Compounds</article-title>,&#8221; <source>Methods and Protocols</source><volume>2451</volume> (<year>2022</year>): <fpage>245</fpage>&#8211;<lpage>258</lpage>, <pub-id pub-id-type="doi">10.1007/978-1-0716-2099-1_17</pub-id>.<pub-id pub-id-type="pmid">35505022</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jbio70005-cit-0015"><string-name name-style="western"><given-names>N. J.</given-names><surname>Farrer</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Salassa</surname></string-name>, and <string-name name-style="western"><given-names>P. J.</given-names><surname>Sadler</surname></string-name>, &#8220;<article-title>Photoactivated Chemotherapy (PACT): The Potential of Excited&#8208;State d&#8208;Block Metals in Medicine</article-title>,&#8221; <source>Dalton Transactions</source><volume>48</volume> (<year>2009</year>): <fpage>10690</fpage>&#8211;<lpage>10701</lpage>, <pub-id pub-id-type="doi">10.1039/b917753a</pub-id>.<pub-id pub-id-type="pmcid">PMC2933824</pub-id><pub-id pub-id-type="pmid">20023896</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jbio70005-cit-0016"><string-name name-style="western"><given-names>A.</given-names><surname>Dao</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Pan</surname></string-name>, et&#160;al., &#8220;<article-title>A 700 nm LED Light Activated Ru(II) Complex Destroys Tumour Cytoskeleton via Photosensitization and Photocatalysis</article-title>,&#8221; <source>Advanced Healthcare Materials</source><volume>13</volume> (<year>2024</year>): <elocation-id>2400956</elocation-id>, <pub-id pub-id-type="doi">10.1002/adhm.202400956</pub-id>.<pub-id pub-id-type="pmid">38635863</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jbio70005-cit-0017"><string-name name-style="western"><given-names>D.</given-names><surname>Aebisher</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Rog&#243;&#380;</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>My&#347;liwiec</surname></string-name>, et&#160;al., &#8220;<article-title>The Use of Photodynamic Therapy in Medical Practice</article-title>,&#8221; <source>Frontiers in Oncology</source><volume>14</volume> (<year>2024</year>): <elocation-id>1373263</elocation-id>, <pub-id pub-id-type="doi">10.3389/fonc.2024.1373263</pub-id>.<pub-id pub-id-type="pmid">38803535</pub-id><pub-id pub-id-type="pmcid">PMC11129581</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jbio70005-cit-0018"><string-name name-style="western"><given-names>S.</given-names><surname>Bonnet</surname></string-name>, &#8220;<article-title>Why Develop Photoactivated Chemotherapy?</article-title>,&#8221; <source>Dalton Transactions</source><volume>47</volume> (<year>2018</year>): <fpage>10330</fpage>&#8211;<lpage>10343</lpage>, <pub-id pub-id-type="doi">10.1039/C8DT01585F</pub-id>.<pub-id pub-id-type="pmid">29978870</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jbio70005-cit-0019"><string-name name-style="western"><given-names>A. M.</given-names><surname>Oluwajembola</surname></string-name>, <string-name name-style="western"><given-names>W. D.</given-names><surname>Cleanclay</surname></string-name>, <string-name name-style="western"><given-names>A. F.</given-names><surname>Onyia</surname></string-name>, et&#160;al., &#8220;<article-title>Photosensitizers in Photodynamic Therapy: An Advancement in Cancer Treatment</article-title>,&#8221; <source>Results in Chemistry</source><volume>10</volume> (<year>2024</year>): <elocation-id>101715</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.rechem.2024.101715</pub-id>.</mixed-citation></ref><ref id="jbio70005-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jbio70005-cit-0020"><string-name name-style="western"><given-names>T. A.</given-names><surname>Debele</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Peng</surname></string-name>, and <string-name name-style="western"><given-names>H.&#8208;C.</given-names><surname>Tsai</surname></string-name>, &#8220;<article-title>Drug Carrier for Photodynamic Cancer Therapy</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>16</volume> (<year>2015</year>): <fpage>22094</fpage>&#8211;<lpage>22136</lpage>, <pub-id pub-id-type="doi">10.3390/ijms160922094</pub-id>.<pub-id pub-id-type="pmid">26389879</pub-id><pub-id pub-id-type="pmcid">PMC4613299</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jbio70005-cit-0021"><string-name name-style="western"><given-names>A.</given-names><surname>Casas</surname></string-name>, &#8220;<article-title>Clinical Uses of 5&#8208;Aminolaevulinic Acid in Photodynamic Treatment and Photodetection of Cancer: A Review</article-title>,&#8221; <source>Cancer Letters</source><volume>490</volume> (<year>2020</year>): <fpage>165</fpage>&#8211;<lpage>173</lpage>, <pub-id pub-id-type="doi">10.1016/j.canlet.2020.06.008</pub-id>.<pub-id pub-id-type="pmid">32534172</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jbio70005-cit-0022"><string-name name-style="western"><given-names>Y.</given-names><surname>Hou</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Pathological Mechanism of Photodynamic Therapy and Photothermal Therapy Based on Nanoparticles</article-title>,&#8221; <source>International Journal of Nanomedicine</source><volume>15</volume> (<year>2020</year>): <fpage>6827</fpage>&#8211;<lpage>6838</lpage>, <pub-id pub-id-type="doi">10.2147/IJN.S269321</pub-id>.<pub-id pub-id-type="pmid">32982235</pub-id><pub-id pub-id-type="pmcid">PMC7501968</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jbio70005-cit-0023"><string-name name-style="western"><given-names>I.</given-names><surname>Postiglione</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Chiaviello</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Palumbo</surname></string-name>, &#8220;<article-title>Enhancing Photodynamyc Therapy Efficacy by Combination Therapy: Dated, Current and Oncoming Strategies</article-title>,&#8221; <source>Cancers</source><volume>3</volume>, no. <issue>2</issue> (<year>2011</year>): <fpage>2597</fpage>&#8211;<lpage>2629</lpage>, <pub-id pub-id-type="doi">10.3390/cancers3022597</pub-id>.<pub-id pub-id-type="pmid">24212824</pub-id><pub-id pub-id-type="pmcid">PMC3757433</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jbio70005-cit-0024"><string-name name-style="western"><given-names>A. P.</given-names><surname>Castano</surname></string-name>, <string-name name-style="western"><given-names>T. N.</given-names><surname>Demidova</surname></string-name>, and <string-name name-style="western"><given-names>M. R.</given-names><surname>Hamblin</surname></string-name>, &#8220;<article-title>Mechanisms in Photodynamic Therapy: Part Two&#8212;Cellular Signaling, Cell Metabolism and Modes of Cell Death</article-title>,&#8221; <source>Photodiagnosis and Photodynamic Therapy</source><volume>2</volume> (<year>2005</year>): <fpage>1</fpage>&#8211;<lpage>23</lpage>, <pub-id pub-id-type="doi">10.1016/S1572-1000(05)00030-X</pub-id>.<pub-id pub-id-type="pmid">25048553</pub-id><pub-id pub-id-type="pmcid">PMC4108176</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jbio70005-cit-0025"><string-name name-style="western"><given-names>H. S.</given-names><surname>Hwang</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Shin</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Han</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Na</surname></string-name>, &#8220;<article-title>Combination of Photodynamic Therapy (PDT) and Anti&#8208;Tumour Immunity in Cancer Therapy</article-title>,&#8221; <source>Journal of Pharmaceutical Investigation</source><volume>48</volume> (<year>2018</year>): <fpage>143</fpage>&#8211;<lpage>151</lpage>, <pub-id pub-id-type="doi">10.1007/s40005-017-0377-x</pub-id>.<pub-id pub-id-type="pmid">30680248</pub-id><pub-id pub-id-type="pmcid">PMC6323106</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jbio70005-cit-0026"><string-name name-style="western"><given-names>R.</given-names><surname>Alzeibak</surname></string-name>, <string-name name-style="western"><given-names>T. A.</given-names><surname>Mishchenko</surname></string-name>, <string-name name-style="western"><given-names>N. Y.</given-names><surname>Shilyagina</surname></string-name>, <string-name name-style="western"><given-names>I. V.</given-names><surname>Balalaeva</surname></string-name>, <string-name name-style="western"><given-names>M. V.</given-names><surname>Vedunova</surname></string-name>, and <string-name name-style="western"><given-names>D. V.</given-names><surname>Krysko</surname></string-name>, &#8220;<article-title>Targeting Immunogenic Cancer Cell Death by Photodynamic Therapy: Past, Present and Future</article-title>,&#8221; <source>Journal for Immunotherapy of Cancer</source><volume>9</volume> (<year>2021</year>): <elocation-id>e001926</elocation-id>, <pub-id pub-id-type="doi">10.1136/jitc-2020-001926</pub-id>.<pub-id pub-id-type="pmid">33431631</pub-id><pub-id pub-id-type="pmcid">PMC7802670</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jbio70005-cit-0027"><string-name name-style="western"><given-names>H.</given-names><surname>Abrahamse</surname></string-name> and <string-name name-style="western"><given-names>M. R.</given-names><surname>Hamblin</surname></string-name>, &#8220;<article-title>New Photosensitizers for Photodynamic Therapy</article-title>,&#8221; <source>Biochemical Journal</source><volume>473</volume> (<year>2016</year>): <fpage>347</fpage>&#8211;<lpage>364</lpage>, <pub-id pub-id-type="doi">10.1042/BJ20150942</pub-id>.<pub-id pub-id-type="pmid">26862179</pub-id><pub-id pub-id-type="pmcid">PMC4811612</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jbio70005-cit-0028"><string-name name-style="western"><given-names>L. P.</given-names><surname>Roguin</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Chiarante</surname></string-name>, <string-name name-style="western"><given-names>M. C.</given-names><surname>Garc&#237;a Vior</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Marino</surname></string-name>, &#8220;<article-title>Zinc(II) Phthalocyanines as Photosensitizers for Antitumour Photodynamic Therapy</article-title>,&#8221; <source>International Journal of Biochemistry &amp; Cell Biology</source><volume>114</volume> (<year>2019</year>): <elocation-id>105575</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.biocel.2019.105575</pub-id>.<pub-id pub-id-type="pmid">31362060</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jbio70005-cit-0029"><string-name name-style="western"><given-names>A.</given-names><surname>Oniszczuk</surname></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>Wojtunik&#8208;Kulesza</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Oniszczuk</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Kasprzak</surname></string-name>, &#8220;<article-title>The Potential of Photodynamic Therapy (PDT)&#8212;Experimental Investigations and Clinical Use</article-title>,&#8221; <source>Biomedicine &amp; Pharmacotherapy</source><volume>83</volume> (<year>2016</year>): <fpage>912</fpage>&#8211;<lpage>929</lpage>, <pub-id pub-id-type="doi">10.1016/j.biopha.2016.07.058</pub-id>.<pub-id pub-id-type="pmid">27522005</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jbio70005-cit-0030"><string-name name-style="western"><given-names>S.</given-names><surname>Gomez</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Tsung</surname></string-name>, and <string-name name-style="western"><given-names>Z.</given-names><surname>Hu</surname></string-name>, &#8220;<article-title>Current Targets and Bioconjugation Strategies in Photodynamic Diagnosis and Therapy of Cancer</article-title>,&#8221; <source>Molecules</source><volume>25</volume> (<year>2020</year>): <elocation-id>4964</elocation-id>, <pub-id pub-id-type="doi">10.3390/molecules25214964</pub-id>.<pub-id pub-id-type="pmid">33121022</pub-id><pub-id pub-id-type="pmcid">PMC7662882</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jbio70005-cit-0031"><string-name name-style="western"><given-names>E. J.</given-names><surname>Hong</surname></string-name>, <string-name name-style="western"><given-names>D. G.</given-names><surname>Choi</surname></string-name>, and <string-name name-style="western"><given-names>M. S.</given-names><surname>Shim</surname></string-name>, &#8220;<article-title>Targeted and Effective Photodynamic Therapy for Cancer Using Functionalized Nanomaterials</article-title>,&#8221; <source>Acta Pharmaceutica Sinica B</source><volume>6</volume> (<year>2016</year>): <fpage>297</fpage>&#8211;<lpage>307</lpage>, <pub-id pub-id-type="doi">10.1016/j.apsb.2016.01.007</pub-id>.<pub-id pub-id-type="pmid">27471670</pub-id><pub-id pub-id-type="pmcid">PMC4951583</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jbio70005-cit-0032"><string-name name-style="western"><given-names>M.</given-names><surname>Aires&#8208;Fernandes</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Botelho Costa</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Rochetti do Amaral</surname></string-name>, <string-name name-style="western"><given-names>C. U.</given-names><surname>Mussagy</surname></string-name>, <string-name name-style="western"><given-names>V. C.</given-names><surname>Santos&#8208;Ebinuma</surname></string-name>, and <string-name name-style="western"><given-names>F. L.</given-names><surname>Primo</surname></string-name>, &#8220;<article-title>Development of Biotechnological Photosensitizers for Photodynamic Therapy: Cancer Research and Treatment&#8212;From Benchtop to Clinical Practice</article-title>,&#8221; <source>Molecules</source><volume>27</volume> (<year>2022</year>): <elocation-id>6848</elocation-id>, <pub-id pub-id-type="doi">10.3390/molecules27206848</pub-id>.<pub-id pub-id-type="pmid">36296441</pub-id><pub-id pub-id-type="pmcid">PMC9609562</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jbio70005-cit-0033"><string-name name-style="western"><given-names>P.</given-names><surname>Agostinis</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Berg</surname></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>Cengel</surname></string-name>, et&#160;al., &#8220;<article-title>Photodynamic Therapy of Cancer: An Update</article-title>,&#8221; <source>CA: A Cancer Journal for Clinicians</source><volume>61</volume> (<year>2011</year>): <fpage>250</fpage>&#8211;<lpage>281</lpage>, <pub-id pub-id-type="doi">10.3322/caac.20114</pub-id>.<pub-id pub-id-type="pmid">21617154</pub-id><pub-id pub-id-type="pmcid">PMC3209659</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jbio70005-cit-0034"><string-name name-style="western"><given-names>C.</given-names><surname>Naidoo</surname></string-name>, <string-name name-style="western"><given-names>C. A.</given-names><surname>Kruger</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Abrahamse</surname></string-name>, &#8220;<article-title>Simultaneous Photodiagnosis and Photodynamic Treatment of Metastatic Melanoma</article-title>,&#8221; <source>Molecules</source><volume>24</volume> (<year>2019</year>): <elocation-id>3153</elocation-id>, <pub-id pub-id-type="doi">10.3390/molecules24173153</pub-id>.<pub-id pub-id-type="pmid">31470637</pub-id><pub-id pub-id-type="pmcid">PMC6749501</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jbio70005-cit-0035"><string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>To Reduce Premature Drug Release While Ensuring Burst Intracellular Drug Release of Solid Lipid Nanoparticle&#8208;Based Drug Delivery System With Clathrin Modification</article-title>,&#8221; <source>Nanomedicine</source><volume>15</volume> (<year>2019</year>): <fpage>108</fpage>&#8211;<lpage>118</lpage>, <pub-id pub-id-type="doi">10.1016/j.nano.2018.05.014</pub-id>.<pub-id pub-id-type="pmid">29859268</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jbio70005-cit-0036"><string-name name-style="western"><given-names>A. M.</given-names><surname>Udrea</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Smarandache</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Dinache</surname></string-name>, et&#160;al., &#8220;<article-title>Photosensitizers&#8208;Loaded Nanocarriers for Enhancement of Photodynamic Therapy in Melanoma Treatment</article-title>,&#8221; <source>Pharmaceutics</source><volume>15</volume> (<year>2023</year>): <elocation-id>2124</elocation-id>, <pub-id pub-id-type="doi">10.3390/pharmaceutics15082124</pub-id>.<pub-id pub-id-type="pmid">37631339</pub-id><pub-id pub-id-type="pmcid">PMC10460031</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jbio70005-cit-0037"><string-name name-style="western"><given-names>J.</given-names><surname>Wu</surname></string-name>, &#8220;<article-title>The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application</article-title>,&#8221; <source>Journal of Personalized Medicine</source><volume>11</volume> (<year>2021</year>): <elocation-id>771</elocation-id>, <pub-id pub-id-type="doi">10.3390/jpm11080771</pub-id>.<pub-id pub-id-type="pmid">34442415</pub-id><pub-id pub-id-type="pmcid">PMC8402171</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jbio70005-cit-0038"><string-name name-style="western"><given-names>I. S.</given-names><surname>Mfouo&#8208;Tynga</surname></string-name>, <string-name name-style="western"><given-names>L. D.</given-names><surname>Dias</surname></string-name>, <string-name name-style="western"><given-names>N. M.</given-names><surname>Inada</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Kurachi</surname></string-name>, &#8220;<article-title>Features of Third Generation Photosensitizers Used in Anticancer Photodynamic Therapy: Review</article-title>,&#8221; <source>Photodiagnosis and Photodynamic Therapy</source><volume>34</volume> (<year>2021</year>): <elocation-id>102091</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.pdpdt.2020.102091</pub-id>.<pub-id pub-id-type="pmid">33453423</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jbio70005-cit-0039"><string-name name-style="western"><given-names>M.</given-names><surname>Srinivasan</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Rajabi</surname></string-name>, and <string-name name-style="western"><given-names>S. A.</given-names><surname>Mousa</surname></string-name>, &#8220;<article-title>Multifunctional Nanomaterials and Their Applications in Drug Delivery and Cancer Therapy</article-title>,&#8221; <source>Nanomaterials</source><volume>5</volume> (<year>2015</year>): <fpage>1690</fpage>&#8211;<lpage>1703</lpage>, <pub-id pub-id-type="doi">10.3390/nano5041690</pub-id>.<pub-id pub-id-type="pmid">28347089</pub-id><pub-id pub-id-type="pmcid">PMC5304767</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jbio70005-cit-0040"><string-name name-style="western"><given-names>H.</given-names><surname>Montaseri</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Kruger</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Abrahamse</surname></string-name>, &#8220;<article-title>Inorganic Nanoparticles Applied for Active Targeted Photodynamic Therapy of Breast Cancer</article-title>,&#8221; <source>Pharmaceutics</source><volume>13</volume> (<year>2021</year>): <elocation-id>296</elocation-id>, <pub-id pub-id-type="doi">10.3390/pharmaceutics13030296</pub-id>.<pub-id pub-id-type="pmid">33668307</pub-id><pub-id pub-id-type="pmcid">PMC7996317</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jbio70005-cit-0041"><string-name name-style="western"><given-names>C. A.</given-names><surname>Kruger</surname></string-name> and <string-name name-style="western"><given-names>H.</given-names><surname>Abrahamse</surname></string-name>, &#8220;<article-title>Utilisation of Targeted Nanoparticle Photosensitiser Drug Delivery Systems for the Enhancement of Photodynamic Therapy</article-title>,&#8221; <source>Molecules</source><volume>23</volume> (<year>2018</year>): <elocation-id>2628</elocation-id>, <pub-id pub-id-type="doi">10.3390/molecules23102628</pub-id>.<pub-id pub-id-type="pmid">30322132</pub-id><pub-id pub-id-type="pmcid">PMC6222717</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jbio70005-cit-0042"><string-name name-style="western"><given-names>H.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Tumour&#8208;Targeting, Enzyme&#8208;Activated Nanoparticles for Simultaneous Cancer Diagnosis and Photodynamic Therapy</article-title>,&#8221; <source>Journal of Materials Chemistry B</source><volume>4</volume> (<year>2016</year>): <fpage>113</fpage>&#8211;<lpage>120</lpage>, <pub-id pub-id-type="doi">10.1039/C5TB02041G</pub-id>.<pub-id pub-id-type="pmid">32262814</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="jbio70005-cit-0043"><string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, et&#160;al., &#8220;<article-title>Folic Acid&#8211;Conjugated Pyropheophorbide a as the Photosensitizer Tested for In&#160;Vivo Targeted Photodynamic Therapy</article-title>,&#8221; <source>Journal of Pharmaceutical Sciences</source><volume>106</volume> (<year>2017</year>): <fpage>1482</fpage>&#8211;<lpage>1489</lpage>, <pub-id pub-id-type="doi">10.1016/j.xphs.2017.02.019</pub-id>.<pub-id pub-id-type="pmid">28263847</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="jbio70005-cit-0044"><string-name name-style="western"><given-names>M.</given-names><surname>Baydoun</surname></string-name>, <string-name name-style="western"><given-names>O.</given-names><surname>Moral&#232;s</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Frochot</surname></string-name>, et&#160;al., &#8220;<article-title>Photodynamic Therapy Using a New Folate Receptor&#8208;Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles With Immunoactivating Properties</article-title>,&#8221; <source>Journal of Clinical Medicine</source><volume>9</volume> (<year>2020</year>): <elocation-id>1185</elocation-id>, <pub-id pub-id-type="doi">10.3390/jcm9041185</pub-id>.<pub-id pub-id-type="pmid">32326210</pub-id><pub-id pub-id-type="pmcid">PMC7230754</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="jbio70005-cit-0045"><string-name name-style="western"><given-names>M. N.</given-names><surname>Sardoiwala</surname></string-name>, <string-name name-style="western"><given-names>A. C.</given-names><surname>Kushwaha</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Dev</surname></string-name>, et&#160;al., &#8220;<article-title>Hypericin&#8208;Loaded Transferrin Nanoparticles Induce PP2A&#8208;Regulated BMI1 Degradation in Colorectal Cancer&#8208;Specific Chemo&#8208;Photodynamic Therapy</article-title>,&#8221; <source>ACS Biomaterials Science &amp; Engineering</source><volume>6</volume> (<year>2020</year>): <fpage>3139</fpage>&#8211;<lpage>3153</lpage>, <pub-id pub-id-type="doi">10.1021/acsbiomaterials.9b01844</pub-id>.<pub-id pub-id-type="pmid">33463265</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="jbio70005-cit-0046"><string-name name-style="western"><given-names>Q.</given-names><surname>Pan</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Cheng</surname></string-name>, et&#160;al., &#8220;<article-title>A Photoactivatable Antibody&#8211;Chlorin e6 Conjugate Enabling Singlet Oxygen Production for Tumour&#8208;Targeting Photodynamic Therapy</article-title>,&#8221; <source>Biomedical Materials</source><volume>16</volume> (<year>2021</year>): <elocation-id>045003</elocation-id>, <pub-id pub-id-type="doi">10.1088/1748-605X/ab9f57</pub-id>.<pub-id pub-id-type="pmid">32584266</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="jbio70005-cit-0047"><string-name name-style="western"><given-names>W.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Guo</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Kong</surname></string-name>, et&#160;al., &#8220;<article-title>Overcoming Photodynamic Resistance and Tumour Targeting Dual&#8208;Therapy Mediated by Indocyanine Green Conjugated Gold Nanospheres</article-title>,&#8221; <source>Journal of Controlled Release</source><volume>258</volume> (<year>2017</year>): <fpage>171</fpage>&#8211;<lpage>181</lpage>, <pub-id pub-id-type="doi">10.1016/j.jconrel.2017.05.015</pub-id>.<pub-id pub-id-type="pmid">28522192</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="jbio70005-cit-0048"><string-name name-style="western"><given-names>W.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Tan</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Xing</surname></string-name>, et&#160;al., &#8220;<article-title>cRGD Peptide&#8208;Conjugated Pyropheophorbide&#8212;A Photosensitizers for Tumour Targeting in Photodynamic Therapy</article-title>,&#8221; <source>Molecular Pharmaceutics</source><volume>15</volume> (<year>2018</year>): <fpage>1505</fpage>&#8211;<lpage>1514</lpage>, <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b01064</pub-id>.<pub-id pub-id-type="pmid">29502410</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="jbio70005-cit-0049"><string-name name-style="western"><given-names>H. S.</given-names><surname>Jung</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Shi</surname></string-name>, et&#160;al., &#8220;<article-title>Overcoming the Limits of Hypoxia in Photodynamic Therapy: A Carbonic Anhydrase IX&#8208;Targeted Approach</article-title>,&#8221; <source>Journal of the American Chemical Society</source><volume>139</volume> (<year>2017</year>): <fpage>7595</fpage>&#8211;<lpage>7602</lpage>, <pub-id pub-id-type="doi">10.1021/jacs.7b02396</pub-id>.<pub-id pub-id-type="pmid">28459562</pub-id><pub-id pub-id-type="pmcid">PMC5772932</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="jbio70005-cit-0050"><string-name name-style="western"><given-names>A. A.</given-names><surname>Sebak</surname></string-name>, <string-name name-style="western"><given-names>I. E. O.</given-names><surname>Gomaa</surname></string-name>, <string-name name-style="western"><given-names>A. N.</given-names><surname>ElMeshad</surname></string-name>, and <string-name name-style="western"><given-names>M. H.</given-names><surname>AbdelKader</surname></string-name>, &#8220;<article-title>Targeted Photodynamic&#8208;Induced Singlet Oxygen Production by Peptide&#8208;Conjugated Biodegradable Nanoparticles for Treatment of Skin Melanoma</article-title>,&#8221; <source>Photodiagnosis and Photodynamic Therapy</source><volume>23</volume> (<year>2018</year>): <fpage>181</fpage>&#8211;<lpage>189</lpage>, <pub-id pub-id-type="doi">10.1016/j.pdpdt.2018.05.017</pub-id>.<pub-id pub-id-type="pmid">29885810</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="jbio70005-cit-0051"><string-name name-style="western"><given-names>H.</given-names><surname>Montaseri</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Kruger</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Abrahamse</surname></string-name>, &#8220;<article-title>Targeted Photodynamic Therapy Using Alloyed Nanoparticle&#8208;Conjugated 5&#8208;Aminolevulinic Acid for Breast Cancer</article-title>,&#8221; <source>Pharmaceutics</source><volume>13</volume> (<year>2021</year>): <elocation-id>1375</elocation-id>, <pub-id pub-id-type="doi">10.3390/pharmaceutics13091375</pub-id>.<pub-id pub-id-type="pmid">34575450</pub-id><pub-id pub-id-type="pmcid">PMC8471498</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="jbio70005-cit-0052"><string-name name-style="western"><given-names>X.</given-names><surname>Tan</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Pang</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Lei</surname></string-name>, et&#160;al., &#8220;<article-title>An Efficient Dual&#8208;Loaded Multifunctional Nanocarrier for Combined Photothermal and Photodynamic Therapy Based on Copper Sulfide and Chlorin e6</article-title>,&#8221; <source>International Journal of Pharmaceutics</source><volume>503</volume> (<year>2016</year>): <fpage>220</fpage>&#8211;<lpage>228</lpage>, <pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.03.019</pub-id>.<pub-id pub-id-type="pmid">26988376</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="jbio70005-cit-0053"><string-name name-style="western"><given-names>X.</given-names><surname>Lin</surname></string-name>, <string-name name-style="western"><given-names>S.&#8208;Z.</given-names><surname>Yan</surname></string-name>, <string-name name-style="western"><given-names>S.&#8208;S.</given-names><surname>Qi</surname></string-name>, et&#160;al., &#8220;<article-title>Transferrin&#8208;Modified Nanoparticles for Photodynamic Therapy Enhance the Antitumour Efficacy of Hypocrellin A</article-title>,&#8221; <source>Frontiers in Pharmacology</source><volume>8</volume> (<year>2017</year>): <elocation-id>815</elocation-id>, <pub-id pub-id-type="doi">10.3389/fphar.2017.00815</pub-id>.<pub-id pub-id-type="pmid">29209206</pub-id><pub-id pub-id-type="pmcid">PMC5701649</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="jbio70005-cit-0054"><string-name name-style="western"><given-names>S.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Tian</surname></string-name>, et&#160;al., &#8220;<article-title>Construction and Evaluation of a Targeted Hyaluronic Acid Nanoparticle/Photosensitizer Complex for Cancer Photodynamic Therapy</article-title>,&#8221; <source>ACS Applied Materials &amp; Interfaces</source><volume>9</volume> (<year>2017</year>): <fpage>32509</fpage>&#8211;<lpage>32519</lpage>, <pub-id pub-id-type="doi">10.1021/acsami.7b09331</pub-id>.<pub-id pub-id-type="pmid">28875691</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="jbio70005-cit-0055"><string-name name-style="western"><given-names>D.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Zheng</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, et&#160;al., &#8220;<article-title>Smart Cu(II)&#8208;Aptamer Complexes Based Gold Nanoplatform for Tumour Micro&#8208;Environment Triggered Programmable Intracellular Prodrug Release, Photodynamic Treatment and Aggregation Induced Photothermal Therapy of Hepatocellular Carcinoma</article-title>,&#8221; <source>Theranostics</source><volume>7</volume> (<year>2017</year>): <fpage>164</fpage>&#8211;<lpage>179</lpage>, <pub-id pub-id-type="doi">10.7150/thno.17099</pub-id>.<pub-id pub-id-type="pmid">28042325</pub-id><pub-id pub-id-type="pmcid">PMC5196894</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="jbio70005-cit-0056"><string-name name-style="western"><given-names>Q.</given-names><surname>Hu</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Feng</surname></string-name>, et&#160;al., &#8220;<article-title>Tumour Microenvironment and Angiogenic Blood Vessels Dual&#8208;Targeting for Enhanced Anti&#8208;Glioma Therapy</article-title>,&#8221; <source>ACS Applied Materials &amp; Interfaces</source><volume>8</volume> (<year>2016</year>): <fpage>23568</fpage>&#8211;<lpage>23579</lpage>, <pub-id pub-id-type="doi">10.1021/acsami.6b08239</pub-id>.<pub-id pub-id-type="pmid">27580101</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="jbio70005-cit-0057"><string-name name-style="western"><given-names>F. M.</given-names><surname>Kievit</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>A. E.</given-names><surname>Erickson</surname></string-name>, <string-name name-style="western"><given-names>S. K. L.</given-names><surname>Levengood</surname></string-name>, <string-name name-style="western"><given-names>R. G.</given-names><surname>Ellenbogen</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Zhang</surname></string-name>, &#8220;<article-title>Modeling the Tumour Microenvironment Using Chitosan&#8208;Alginate Scaffolds to Control the Stem&#8208;Like State of Glioblastoma Cells</article-title>,&#8221; <source>Biomaterials Science</source><volume>4</volume> (<year>2016</year>): <fpage>610</fpage>&#8211;<lpage>613</lpage>, <pub-id pub-id-type="doi">10.1039/C5BM00514K</pub-id>.<pub-id pub-id-type="pmid">26688867</pub-id><pub-id pub-id-type="pmcid">PMC4803622</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="jbio70005-cit-0058"><string-name name-style="western"><given-names>J.</given-names><surname>Yao</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Feng</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Gao</surname></string-name>, et&#160;al., &#8220;<article-title>Neovasculature and Circulating Tumour Cells Dual&#8208;Targeting Nanoparticles for the Treatment of the Highly&#8208;Invasive Breast Cancer</article-title>,&#8221; <source>Biomaterials</source><volume>113</volume> (<year>2017</year>): <fpage>1</fpage>&#8211;<lpage>17</lpage>, <pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.10.033</pub-id>.<pub-id pub-id-type="pmid">27794222</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="jbio70005-cit-0059"><string-name name-style="western"><given-names>F. C. P.</given-names><surname>Rosin</surname></string-name>, <string-name name-style="western"><given-names>M. G.</given-names><surname>Teixeira</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Pelissari</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Corr&#234;a</surname></string-name>, &#8220;<article-title>Resistance of Oral Cancer Cells to 5&#8208;ALA&#8208;Mediated Photodynamic Therapy</article-title>,&#8221; <source>Journal of Cellular Biochemistry</source><volume>119</volume> (<year>2018</year>): <fpage>3554</fpage>&#8211;<lpage>3562</lpage>, <pub-id pub-id-type="doi">10.1002/jcb.26541</pub-id>.<pub-id pub-id-type="pmid">29227548</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="jbio70005-cit-0060"><string-name name-style="western"><given-names>Y.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Xiao</surname></string-name>, et&#160;al., &#8220;<article-title>Polypeptide Uploaded Efficient Nanophotosensitizers to Overcome Photodynamic Resistance for Enhanced Anticancer Therapy</article-title>,&#8221; <source>Chemical Engineering Journal</source><volume>403</volume> (<year>2021</year>): <elocation-id>126344</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.cej.2020.126344</pub-id>.</mixed-citation></ref><ref id="jbio70005-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="jbio70005-cit-0061"><string-name name-style="western"><given-names>T.&#8208;J.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Xing</surname></string-name>, <string-name name-style="western"><given-names>Y.&#8208;T.</given-names><surname>Fan</surname></string-name>, <string-name name-style="western"><given-names>P.&#8208;F.</given-names><surname>Cui</surname></string-name>, and <string-name name-style="western"><given-names>H.&#8208;L.</given-names><surname>Jiang</surname></string-name>, &#8220;<article-title>Light Triggered Oxygen&#8208;Affording Engines for Repeated Hypoxia&#8208;Resistant Photodynamic Therapy</article-title>,&#8221; <source>Journal of Controlled Release</source><volume>307</volume> (<year>2019</year>): <fpage>44</fpage>&#8211;<lpage>54</lpage>, <pub-id pub-id-type="doi">10.1016/j.jconrel.2019.06.016</pub-id>.<pub-id pub-id-type="pmid">31202726</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="jbio70005-cit-0062"><string-name name-style="western"><given-names>N.</given-names><surname>Nkune</surname></string-name> and <string-name name-style="western"><given-names>H.</given-names><surname>Abrahamse</surname></string-name>, &#8220;<article-title>Anti&#8208;Hypoxia Nanoplatforms for Enhanced Photosensitizer Uptake and Photodynamic Therapy Effects in Cancer Cells</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>24</volume> (<year>2023</year>): <elocation-id>2656</elocation-id>, <pub-id pub-id-type="doi">10.3390/ijms24032656</pub-id>.<pub-id pub-id-type="pmid">36768975</pub-id><pub-id pub-id-type="pmcid">PMC9916860</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="jbio70005-cit-0063"><string-name name-style="western"><given-names>U.</given-names><surname>Das</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Kar</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Pete</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Paira</surname></string-name>, &#8220;<article-title>Ru(II), Ir(III), Re(I) and Rh(III) Based Complexes as Next Generation Anticancer Metallopharmaceuticals</article-title>,&#8221; <source>Dalton Transactions</source><volume>50</volume> (<year>2021</year>): <fpage>11259</fpage>&#8211;<lpage>11290</lpage>, <pub-id pub-id-type="doi">10.1039/D1DT01326B</pub-id>.<pub-id pub-id-type="pmid">34342316</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="jbio70005-cit-0064"><string-name name-style="western"><given-names>D. L.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>H. Z.</given-names><surname>He</surname></string-name>, <string-name name-style="western"><given-names>K. H.</given-names><surname>Leung</surname></string-name>, <string-name name-style="western"><given-names>D. S. H.</given-names><surname>Chan</surname></string-name>, and <string-name name-style="western"><given-names>C. H.</given-names><surname>Leung</surname></string-name>, &#8220;<article-title>Bioactive Luminescent Transition&#8208;Metal Complexes for Biomedical Applications</article-title>,&#8221; <source>Angewandte Chemie International Edition</source><volume>52</volume>, no. <issue>30</issue> (<year>2013</year>): <fpage>7666</fpage>&#8211;<lpage>7682</lpage>, <pub-id pub-id-type="doi">10.1002/anie.201208414</pub-id>.<pub-id pub-id-type="pmid">23765907</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="jbio70005-cit-0065"><string-name name-style="western"><given-names>D.&#8208;L.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>K.&#8208;J.</given-names><surname>Wu</surname></string-name>, and <string-name name-style="western"><given-names>C.&#8208;H.</given-names><surname>Leung</surname></string-name>, &#8220;<article-title>Iridium(III) Complexes Targeting Apoptotic Cell Death in Cancer Cells</article-title>,&#8221; <source>Molecules</source><volume>24</volume> (<year>2019</year>): <elocation-id>2739</elocation-id>, <pub-id pub-id-type="doi">10.3390/molecules24152739</pub-id>.<pub-id pub-id-type="pmid">31357712</pub-id><pub-id pub-id-type="pmcid">PMC6696146</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="jbio70005-cit-0066"><string-name name-style="western"><given-names>K. D.</given-names><surname>Mjos</surname></string-name> and <string-name name-style="western"><given-names>C.</given-names><surname>Orvig</surname></string-name>, &#8220;<article-title>Metallodrugs in Medicinal Inorganic Chemistry</article-title>,&#8221; <source>Chemical Reviews</source><volume>114</volume>, no. <issue>2014</issue> (<year>2014</year>): <fpage>4540</fpage>&#8211;<lpage>4563</lpage>, <pub-id pub-id-type="doi">10.1021/cr400460s</pub-id>.<pub-id pub-id-type="pmid">24456146</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="jbio70005-cit-0067"><string-name name-style="western"><given-names>J.</given-names><surname>Ohata</surname></string-name> and <string-name name-style="western"><given-names>Z. T.</given-names><surname>Ball</surname></string-name>, &#8220;<article-title>Rhodium at the Chemistry&#8211;Biology Interface</article-title>,&#8221; <source>Dalton Transactions</source><volume>47</volume> (<year>2018</year>): <fpage>14855</fpage>&#8211;<lpage>14860</lpage>, <pub-id pub-id-type="doi">10.1039/C8DT03032D</pub-id>.<pub-id pub-id-type="pmid">30234200</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="jbio70005-cit-0068"><string-name name-style="western"><given-names>R. O.</given-names><surname>Omondi</surname></string-name>, <string-name name-style="western"><given-names>S. O.</given-names><surname>Ojwach</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Jaganyi</surname></string-name>, &#8220;<article-title>Review of Comparative Studies of Cytotoxic Activities of Pt(II), Pd(II), Ru(II)/(III) and Au(III) Complexes, Their Kinetics of Ligand Substitution Reactions and DNA/BSA Interactions</article-title>,&#8221; <source>Inorganica Chimica Acta</source><volume>512</volume> (<year>2020</year>): <elocation-id>119883</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.ica.2020.119883</pub-id>.</mixed-citation></ref><ref id="jbio70005-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="jbio70005-cit-0069"><string-name name-style="western"><given-names>N. J.</given-names><surname>Wheate</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Walker</surname></string-name>, <string-name name-style="western"><given-names>G. E.</given-names><surname>Craig</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Oun</surname></string-name>, &#8220;<article-title>The Status of Platinum Anticancer Drugs in the Clinic and in Clinical Trials</article-title>,&#8221; <source>Dalton Transactions</source><volume>39</volume> (<year>2010</year>): <fpage>8113</fpage>&#8211;<lpage>8127</lpage>, <pub-id pub-id-type="doi">10.1039/c0dt00292e</pub-id>.<pub-id pub-id-type="pmid">20593091</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="jbio70005-cit-0070"><string-name name-style="western"><given-names>G.</given-names><surname>Ms</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Ma</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Bk</surname></string-name>, &#8220;<article-title>Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches</article-title>,&#8221; <source>Current Medicinal Chemistry</source><volume>12</volume>, no. <issue>18</issue> (<year>2005</year>): <fpage>2075</fpage>&#8211;<lpage>2094</lpage>, <pub-id pub-id-type="doi">10.2174/0929867054637626</pub-id>.<pub-id pub-id-type="pmid">16101495</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="jbio70005-cit-0071"><string-name name-style="western"><given-names>N.</given-names><surname>Graf</surname></string-name>, <string-name name-style="western"><given-names>D. R.</given-names><surname>Bielenberg</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Kolishetti</surname></string-name>, et&#160;al., &#8220;<article-title>&#945;V&#946;3 Integrin&#8208;Targeted PLGA&#8208;PEG Nanoparticles for Enhanced Anti&#8208;Tumour Efficacy of a Pt(IV) Prodrug</article-title>,&#8221; <source>ACS Nano</source><volume>6</volume> (<year>2012</year>): <fpage>4530</fpage>&#8211;<lpage>4539</lpage>, <pub-id pub-id-type="doi">10.1021/nn301148e</pub-id>.<pub-id pub-id-type="pmid">22584163</pub-id><pub-id pub-id-type="pmcid">PMC3358506</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="jbio70005-cit-0072"><string-name name-style="western"><given-names>Y.&#8208;R.</given-names><surname>Zheng</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Suntharalingam</surname></string-name>, <string-name name-style="western"><given-names>T. C.</given-names><surname>Johnstone</surname></string-name>, et&#160;al., &#8220;<article-title>Pt(IV) Prodrugs Designed to Bind Non&#8208;Covalently to Human Serum Albumin for Drug Delivery</article-title>,&#8221; <source>Journal of the American Chemical Society</source><volume>136</volume> (<year>2014</year>): <fpage>8790</fpage>&#8211;<lpage>8798</lpage>, <pub-id pub-id-type="doi">10.1021/ja5038269</pub-id>.<pub-id pub-id-type="pmid">24902769</pub-id><pub-id pub-id-type="pmcid">PMC4076294</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="jbio70005-cit-0073"><string-name name-style="western"><given-names>K.</given-names><surname>Suntharalingam</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Song</surname></string-name>, and <string-name name-style="western"><given-names>S. J.</given-names><surname>Lippard</surname></string-name>, &#8220;<article-title>Conjugation of Vitamin E Analog &#945;&#8208;TOS to Pt(IV) Complexes for Dual&#8208;Targeting Anticancer Therapy</article-title>,&#8221; <source>Chemical Communications</source><volume>50</volume> (<year>2014</year>): <fpage>2465</fpage>&#8211;<lpage>2468</lpage>, <pub-id pub-id-type="doi">10.1039/C3CC48740G</pub-id>.<pub-id pub-id-type="pmid">24452361</pub-id><pub-id pub-id-type="pmcid">PMC3938893</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="jbio70005-cit-0074"><string-name name-style="western"><given-names>M.</given-names><surname>Fanelli</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Formica</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Fusi</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Giorgi</surname></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Micheloni</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Paoli</surname></string-name>, &#8220;<article-title>New Trends in Platinum and Palladium Complexes as Antineoplastic Agents</article-title>,&#8221; <source>Coordination Chemistry Reviews</source><volume>310</volume> (<year>2016</year>): <fpage>41</fpage>&#8211;<lpage>79</lpage>, <pub-id pub-id-type="doi">10.1016/j.ccr.2015.11.004</pub-id>.</mixed-citation></ref><ref id="jbio70005-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="jbio70005-cit-0075"><string-name name-style="western"><given-names>N. J.</given-names><surname>Farrer</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Woods</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Salassa</surname></string-name>, et&#160;al., &#8220;<article-title>A Potent Trans&#8208;Diimine Platinum Anticancer Complex Photoactivated by Visible Light</article-title>,&#8221; <source>Angewandte Chemie (International Ed. in English)</source><volume>49</volume> (<year>2010</year>): <fpage>9089</fpage>&#8211;<lpage>9092</lpage>, <pub-id pub-id-type="doi">10.1002/anie.201003399</pub-id>.<pub-id pub-id-type="pmid">20677309</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="jbio70005-cit-0076"><string-name name-style="western"><given-names>C.</given-names><surname>Imberti</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Huang</surname></string-name>, and <string-name name-style="western"><given-names>P. J.</given-names><surname>Sadler</surname></string-name>, &#8220;<article-title>New Designs for Phototherapeutic Transition Metal Complexes</article-title>,&#8221; <source>Angewandte Chemie International Edition</source><volume>59</volume> (<year>2020</year>): <fpage>61</fpage>&#8211;<lpage>73</lpage>, <pub-id pub-id-type="doi">10.1002/anie.201905171</pub-id>.<pub-id pub-id-type="pmid">31310436</pub-id><pub-id pub-id-type="pmcid">PMC6973108</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="jbio70005-cit-0077"><string-name name-style="western"><given-names>K. L.</given-names><surname>Eales</surname></string-name>, <string-name name-style="western"><given-names>K. E. R.</given-names><surname>Hollinshead</surname></string-name>, and <string-name name-style="western"><given-names>D. A.</given-names><surname>Tennant</surname></string-name>, &#8220;<article-title>Hypoxia and Metabolic Adaptation of Cancer Cells</article-title>,&#8221; <source>Oncogene</source><volume>5</volume> (<year>2016</year>): <elocation-id>e190</elocation-id>, <pub-id pub-id-type="doi">10.1038/oncsis.2015.50</pub-id>.<pub-id pub-id-type="pmcid">PMC4728679</pub-id><pub-id pub-id-type="pmid">26807645</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="jbio70005-cit-0078"><string-name name-style="western"><given-names>J.&#8208;P.</given-names><surname>Cosse</surname></string-name> and <string-name name-style="western"><given-names>C.</given-names><surname>Michiels</surname></string-name>, &#8220;<article-title>Tumour Hypoxia Affects the Responsiveness of Cancer Cells to Chemotherapy and Promotes Cancer Progression</article-title>,&#8221; <source>Anti&#8208;Cancer Agents in Medicinal Chemistry</source><volume>8</volume>, no. <issue>7</issue> (<year>2008</year>): <fpage>790</fpage>&#8211;<lpage>797</lpage>, <pub-id pub-id-type="doi">10.2174/187152008785914798</pub-id>.<pub-id pub-id-type="pmid">18855580</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="jbio70005-cit-0079"><string-name name-style="western"><given-names>M.</given-names><surname>Alagesan</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Sathyadevi</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Krishnamoorthy</surname></string-name>, <string-name name-style="western"><given-names>N. S. P.</given-names><surname>Bhuvanesh</surname></string-name>, and <string-name name-style="western"><given-names>N.</given-names><surname>Dharmaraj</surname></string-name>, &#8220;<article-title>DMSO Containing Ruthenium(II) Hydrazone Complexes: In&#160;Vitro Evaluation of Biomolecular Interaction and Anticancer Activity</article-title>,&#8221; <source>Dalton Transactions</source><volume>43</volume> (<year>2014</year>): <fpage>15829</fpage>&#8211;<lpage>15840</lpage>, <pub-id pub-id-type="doi">10.1039/c4dt01032a</pub-id>.<pub-id pub-id-type="pmid">25223849</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="jbio70005-cit-0080"><string-name name-style="western"><given-names>Q.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Zhang</surname></string-name>, and <string-name name-style="western"><given-names>Q.</given-names><surname>Zhang</surname></string-name>, &#8220;<article-title>Ruthenium Complexes as Promising Candidates Against Lung Cancer</article-title>,&#8221; <source>Molecules</source><volume>26</volume> (<year>2021</year>): <elocation-id>4389</elocation-id>, <pub-id pub-id-type="doi">10.3390/molecules26154389</pub-id>.<pub-id pub-id-type="pmid">34361543</pub-id><pub-id pub-id-type="pmcid">PMC8348655</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="jbio70005-cit-0081"><string-name name-style="western"><given-names>S.</given-names><surname>Thota</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Rodrigues</surname></string-name>, <string-name name-style="western"><given-names>D. C.</given-names><surname>Crans</surname></string-name>, and <string-name name-style="western"><given-names>E. J.</given-names><surname>Barreiro</surname></string-name>, &#8220;<article-title>Ru(II) Compounds: Next&#8208;Generation Anticancer Metallotherapeutics?</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>61</volume> (<year>2018</year>): <fpage>5805</fpage>&#8211;<lpage>5821</lpage>, <pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b01689</pub-id>.<pub-id pub-id-type="pmid">29446940</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="jbio70005-cit-0082"><string-name name-style="western"><given-names>A.</given-names><surname>Notaro</surname></string-name> and <string-name name-style="western"><given-names>G.</given-names><surname>Gasser</surname></string-name>, &#8220;<article-title>Monomeric and Dimeric Coordinatively Saturated and Substitutionally Inert Ru(II) Polypyridyl Complexes as Anticancer Drug Candidates</article-title>,&#8221; <source>Chemical Society Reviews</source><volume>46</volume> (<year>2017</year>): <fpage>7317</fpage>&#8211;<lpage>7337</lpage>, <pub-id pub-id-type="doi">10.1039/c7cs00356k</pub-id>.<pub-id pub-id-type="pmid">29027562</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="jbio70005-cit-0083"><string-name name-style="western"><given-names>F. E.</given-names><surname>Poynton</surname></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Bright</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Blasco</surname></string-name>, <string-name name-style="western"><given-names>D. C.</given-names><surname>Williams</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Kelly</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Gunnlaugsson</surname></string-name>, &#8220;<article-title>The Development of Ruthenium(II) Polypyridyl Complexes and Conjugates for In&#160;Vitro Cellular and In&#160;Vivo Applications</article-title>,&#8221; <source>Chemical Society Reviews</source><volume>46</volume> (<year>2017</year>): <fpage>7706</fpage>&#8211;<lpage>7756</lpage>, <pub-id pub-id-type="doi">10.1039/C7CS00680B</pub-id>.<pub-id pub-id-type="pmid">29177281</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="jbio70005-cit-0084"><string-name name-style="western"><given-names>A.</given-names><surname>Bergamo</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Zorzet</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Gava</surname></string-name>, et&#160;al., &#8220;<article-title>Effects of NAMI&#8208;A and Some Related Ruthenium Complexes on Cell Viability After Short Exposure of Tumour Cells</article-title>,&#8221; <source>Anti&#8208;Cancer Drugs</source><volume>11</volume> (<year>2000</year>): <fpage>665</fpage>&#8211;<lpage>672</lpage>, <pub-id pub-id-type="doi">10.1097/00001813-200009000-00012</pub-id>.<pub-id pub-id-type="pmid">11081461</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="jbio70005-cit-0085"><string-name name-style="western"><given-names>I.</given-names><surname>Bratsos</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Jedner</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Gianferrara</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Alessio</surname></string-name>, &#8220;<article-title>Ruthenium Anticancer Compounds: Challenges and Expectations</article-title>,&#8221; <source>Chimia</source><volume>61</volume> (<year>2007</year>): <elocation-id>692</elocation-id>, <pub-id pub-id-type="doi">10.2533/chimia.2007.692</pub-id>.</mixed-citation></ref><ref id="jbio70005-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="jbio70005-cit-0086"><string-name name-style="western"><given-names>A. K.</given-names><surname>Bytzek</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Koellensperger</surname></string-name>, <string-name name-style="western"><given-names>B. K.</given-names><surname>Keppler</surname></string-name>, and <string-name name-style="western"><given-names>C. G.</given-names><surname>Hartinger</surname></string-name>, &#8220;<article-title>Biodistribution of the Novel Anticancer Drug Sodium Trans&#8208;[Tetrachloridobis(1H&#8208;Indazole)Ruthenate(III)] KP&#8208;1339/IT139 in Nude BALB/c Mice and Implications on Its Mode of Action</article-title>,&#8221; <source>Journal of Inorganic Biochemistry</source><volume>160</volume> (<year>2016</year>): <fpage>250</fpage>&#8211;<lpage>255</lpage>, <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2016.02.037</pub-id>.<pub-id pub-id-type="pmid">26993078</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="jbio70005-cit-0087"><string-name name-style="western"><given-names>C. G.</given-names><surname>Hartinger</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Zorbas&#8208;Seifried</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Jakupec</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Kynast</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Zorbas</surname></string-name>, and <string-name name-style="western"><given-names>B. K.</given-names><surname>Keppler</surname></string-name>, &#8220;<article-title>From Bench to Bedside&#8212;Preclinical and Early Clinical Development of the Anticancer Agent Indazolium Trans&#8208;[Tetrachlorobis(1H&#8208;Indazole)Ruthenate(III)] (KP1019 or FFC14A)</article-title>,&#8221; <source>Journal of Inorganic Biochemistry</source><volume>100</volume> (<year>2006</year>): <fpage>891</fpage>&#8211;<lpage>904</lpage>, <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2006.02.013</pub-id>.<pub-id pub-id-type="pmid">16603249</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="jbio70005-cit-0088"><string-name name-style="western"><given-names>J. M.</given-names><surname>Rademaker&#8208;Lakhai</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>van den Bongard</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Pluim</surname></string-name>, <string-name name-style="western"><given-names>J. H.</given-names><surname>Beijnen</surname></string-name>, and <string-name name-style="western"><given-names>J. H. M.</given-names><surname>Schellens</surname></string-name>, &#8220;<article-title>A Phase I and Pharmacological Study With Imidazolium&#8208;Trans&#8208;DMSO&#8208;Imidazole&#8208;Tetrachlororuthenate, a Novel Ruthenium Anticancer Agent</article-title>,&#8221; <source>Clinical Cancer Research</source><volume>10</volume> (<year>2004</year>): <fpage>3717</fpage>&#8211;<lpage>3727</lpage>, <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-03-0746</pub-id>.<pub-id pub-id-type="pmid">15173078</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="jbio70005-cit-0089"><string-name name-style="western"><given-names>S.</given-names><surname>Leijen</surname></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Burgers</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Baas</surname></string-name>, et&#160;al., &#8220;<article-title>Phase I/II Study With Ruthenium Compound NAMI&#8208;A and Gemcitabine in Patients With Non&#8208;Small Cell Lung Cancer After First Line Therapy</article-title>,&#8221; <source>Investigational New Drugs</source><volume>33</volume> (<year>2015</year>): <fpage>201</fpage>&#8211;<lpage>214</lpage>, <pub-id pub-id-type="doi">10.1007/s10637-014-0179-1</pub-id>.<pub-id pub-id-type="pmid">25344453</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="jbio70005-cit-0090"><string-name name-style="western"><given-names>M.</given-names><surname>Cocchietto</surname></string-name> and <string-name name-style="western"><given-names>G.</given-names><surname>Sava</surname></string-name>, &#8220;<article-title>Blood Concentration and Toxicity of the Antimetastasis Agent NAMI&#8208;A Following Repeated Intravenous Treatment in Mice</article-title>,&#8221; <source>Pharmacology &amp; Toxicology</source><volume>87</volume> (<year>2000</year>): <fpage>193</fpage>&#8211;<lpage>197</lpage>, <pub-id pub-id-type="doi">10.1034/j.1600-0773.2000.d01-73.x</pub-id>.<pub-id pub-id-type="pmid">11129497</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="jbio70005-cit-0091"><string-name name-style="western"><given-names>P.</given-names><surname>Therasse</surname></string-name>, <string-name name-style="western"><given-names>S. G.</given-names><surname>Arbuck</surname></string-name>, <string-name name-style="western"><given-names>E. A.</given-names><surname>Eisenhauer</surname></string-name>, et&#160;al., &#8220;<article-title>New Guidelines to Evaluate the Response to Treatment in Solid Tumours</article-title>,&#8221; <source>Journal of the National Cancer Institute</source><volume>92</volume> (<year>2000</year>): <fpage>205</fpage>&#8211;<lpage>216</lpage>, <pub-id pub-id-type="doi">10.1093/jnci/92.3.205</pub-id>.<pub-id pub-id-type="pmid">10655437</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="jbio70005-cit-0092"><string-name name-style="western"><given-names>C. G.</given-names><surname>Hartinger</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Jakupec</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Zorbas&#8208;Seifried</surname></string-name>, et&#160;al., &#8220;<article-title>KP1019, a New Redox&#8208;Active Anticancer Agent&#8212;Preclinical Development and Results of a Clinical Phase I Study in Tumour Patients</article-title>,&#8221; <source>Chemistry &amp; Biodiversity</source><volume>5</volume> (<year>2008</year>): <fpage>2140</fpage>&#8211;<lpage>2155</lpage>, <pub-id pub-id-type="doi">10.1002/cbdv.200890195</pub-id>.<pub-id pub-id-type="pmid">18972504</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="jbio70005-cit-0093"><string-name name-style="western"><given-names>R.</given-names><surname>Trondl</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Heffeter</surname></string-name>, <string-name name-style="western"><given-names>C. R.</given-names><surname>Kowol</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Jakupec</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Berger</surname></string-name>, and <string-name name-style="western"><given-names>B. K.</given-names><surname>Keppler</surname></string-name>, &#8220;<article-title>NKP&#8208;1339, the First Ruthenium&#8208;Based Anticancer Drug on the Edge to Clinical Application</article-title>,&#8221; <source>Chemical Science</source><volume>5</volume>, no. <issue>2014</issue> (<year>2014</year>): <fpage>2925</fpage>&#8211;<lpage>2932</lpage>, <pub-id pub-id-type="doi">10.1039/C3SC53243G</pub-id>.</mixed-citation></ref><ref id="jbio70005-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="jbio70005-cit-0094"><string-name name-style="western"><given-names>H. A.</given-names><surname>Burris</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Bakewell</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Bendell</surname></string-name>, et&#160;al., &#8220;<article-title>Safety and Activity of IT&#8208;139, a Ruthenium&#8208;Based Compound, in Patients With Advanced Solid Tumours: A First&#8208;in&#8208;Human, Open&#8208;Label, Dose&#8208;Escalation Phase I Study With Expansion Cohort</article-title>,&#8221; <source>ESMO Open</source><volume>1</volume>, no. <issue>6</issue> (<year>2016</year>): <elocation-id>e000154</elocation-id>, <pub-id pub-id-type="doi">10.1136/esmoopen-2016-000154</pub-id>.<pub-id pub-id-type="pmid">28848672</pub-id><pub-id pub-id-type="pmcid">PMC5548977</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="jbio70005-cit-0095"><string-name name-style="western"><given-names>T.</given-names><surname>Fuereder</surname></string-name> and <string-name name-style="western"><given-names>W.</given-names><surname>Berger</surname></string-name>, &#8220;<article-title>Metal Drugs Become Targeted</article-title>,&#8221; <source>ESMO Open</source><volume>2</volume> (<year>2017</year>): <elocation-id>e000239</elocation-id>, <pub-id pub-id-type="doi">10.1136/esmoopen-2017-000239</pub-id>.<pub-id pub-id-type="pmid">29225925</pub-id><pub-id pub-id-type="pmcid">PMC5604710</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="jbio70005-cit-0096"><string-name name-style="western"><given-names>S.</given-names><surname>Monro</surname></string-name>, <string-name name-style="western"><given-names>K. L.</given-names><surname>Col&#243;n</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Yin</surname></string-name>, et&#160;al., &#8220;<article-title>Transition Metal Complexes and Photodynamic Therapy From a Tumour&#8208;Centered Approach: Challenges, Opportunities, and Highlights From the Development of TLD1433</article-title>,&#8221; <source>Chemical Reviews</source><volume>119</volume> (<year>2019</year>): <fpage>797</fpage>&#8211;<lpage>828</lpage>, <pub-id pub-id-type="doi">10.1021/acs.chemrev.8b00211</pub-id>.<pub-id pub-id-type="pmid">30295467</pub-id><pub-id pub-id-type="pmcid">PMC6453754</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="jbio70005-cit-0097"><string-name name-style="western"><given-names>L.</given-names><surname>Zeng</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Gupta</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Chen</surname></string-name>, et&#160;al., &#8220;<article-title>The Development of Anticancer Ruthenium(II) Complexes: From Single Molecule Compounds to Nanomaterials</article-title>,&#8221; <source>Chemical Society Reviews</source><volume>46</volume> (<year>2017</year>): <fpage>5771</fpage>&#8211;<lpage>5804</lpage>, <pub-id pub-id-type="doi">10.1039/C7CS00195A</pub-id>.<pub-id pub-id-type="pmid">28654103</pub-id><pub-id pub-id-type="pmcid">PMC5624840</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="jbio70005-cit-0098"><string-name name-style="western"><given-names>C.</given-names><surname>Mari</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Pierroz</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ferrari</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Gasser</surname></string-name>, &#8220;<article-title>Combination of Ru(II) Complexes and Light: New Frontiers in Cancer Therapy</article-title>,&#8221; <source>Chemical Science</source><volume>6</volume> (<year>2015</year>): <fpage>2660</fpage>&#8211;<lpage>2686</lpage>, <pub-id pub-id-type="doi">10.1039/C4SC03759F</pub-id>.<pub-id pub-id-type="pmid">29308166</pub-id><pub-id pub-id-type="pmcid">PMC5639435</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="jbio70005-cit-0099"><string-name name-style="western"><given-names>J. D.</given-names><surname>Knoll</surname></string-name> and <string-name name-style="western"><given-names>C.</given-names><surname>Turro</surname></string-name>, &#8220;<article-title>Control and Utilization of Ruthenium and Rhodium Metal Complex Excited States for Photoactivated Cancer Therapy</article-title>,&#8221; <source>Coordination Chemistry Reviews</source><volume>282&#8211;283</volume> (<year>2015</year>): <fpage>110</fpage>&#8211;<lpage>126</lpage>, <pub-id pub-id-type="doi">10.1016/j.ccr.2014.05.018</pub-id>.<pub-id pub-id-type="pmcid">PMC4343038</pub-id><pub-id pub-id-type="pmid">25729089</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="jbio70005-cit-0100"><string-name name-style="western"><given-names>A.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Turro</surname></string-name>, and <string-name name-style="western"><given-names>J. J.</given-names><surname>Kodanko</surname></string-name>, &#8220;<article-title>Ru(II) Polypyridyl Complexes as Photocages for Bioactive Compounds Containing Nitriles and Aromatic Heterocycles</article-title>,&#8221; <source>Chemical Communications</source><volume>54</volume> (<year>2018</year>): <fpage>1280</fpage>&#8211;<lpage>1290</lpage>, <pub-id pub-id-type="doi">10.1039/c7cc09000e</pub-id>.<pub-id pub-id-type="pmid">29323683</pub-id><pub-id pub-id-type="pmcid">PMC5904840</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="jbio70005-cit-0101"><string-name name-style="western"><given-names>M. R.</given-names><surname>Gill</surname></string-name> and <string-name name-style="western"><given-names>J. A.</given-names><surname>Thomas</surname></string-name>, &#8220;<article-title>Ruthenium(II) Polypyridyl Complexes and DNA&#8212;From Structural Probes to Cellular Imaging and Therapeutics</article-title>,&#8221; <source>Chemical Society Reviews</source><volume>41</volume> (<year>2012</year>): <fpage>3179</fpage>&#8211;<lpage>3192</lpage>, <pub-id pub-id-type="doi">10.1039/c2cs15299a</pub-id>.<pub-id pub-id-type="pmid">22314926</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="jbio70005-cit-0102"><string-name name-style="western"><given-names>C. X.</given-names><surname>Zhang</surname></string-name> and <string-name name-style="western"><given-names>S. J.</given-names><surname>Lippard</surname></string-name>, &#8220;<article-title>New Metal Complexes as Potential Therapeutics</article-title>,&#8221; <source>Current Opinion in Chemical Biology</source><volume>7</volume> (<year>2003</year>): <fpage>481</fpage>&#8211;<lpage>489</lpage>, <pub-id pub-id-type="doi">10.1016/S1367-5931(03)00081-4</pub-id>.<pub-id pub-id-type="pmid">12941423</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="jbio70005-cit-0103"><string-name name-style="western"><given-names>Y.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Bai</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Zhao</surname></string-name>, and <string-name name-style="western"><given-names>Q.</given-names><surname>Zhou</surname></string-name>, &#8220;<article-title>The Development of Ru(II)&#8208;Based Photoactivated Chemotherapy Agents</article-title>,&#8221; <source>Molecules</source><volume>26</volume> (<year>2021</year>): <elocation-id>5679</elocation-id>, <pub-id pub-id-type="doi">10.3390/molecules26185679</pub-id>.<pub-id pub-id-type="pmid">34577150</pub-id><pub-id pub-id-type="pmcid">PMC8465985</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="jbio70005-cit-0104"><string-name name-style="western"><given-names>E.</given-names><surname>Dom&#237;nguez&#8208;Jurado</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Lara&#8208;S&#225;nchez</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Bravo</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Oca&#241;a</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Alonso&#8208;Moreno</surname></string-name>, &#8220;<article-title>State of the Art in Organometallic Ruthenium Metallodrugs for Breast Cancer Treatment: Advances and Innovations</article-title>,&#8221; <source>Coordination Chemistry Reviews</source><volume>523</volume> (<year>2025</year>): <elocation-id>216252</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.ccr.2024.216252</pub-id>.</mixed-citation></ref><ref id="jbio70005-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="jbio70005-cit-0105"><string-name name-style="western"><given-names>R.</given-names><surname>Boerhan</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Tian</surname></string-name>, et&#160;al., &#8220;<article-title>Fluorination on Non&#8208;Photolabile Dppz Ligands for Improving Ru(II) Complex&#8208;Based Photoactivated Chemotherapy</article-title>,&#8221; <source>Dalton Transactions</source><volume>48</volume> (<year>2019</year>): <fpage>12177</fpage>&#8211;<lpage>12185</lpage>, <pub-id pub-id-type="doi">10.1039/C9DT01594A</pub-id>.<pub-id pub-id-type="pmid">31334521</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="jbio70005-cit-0106"><string-name name-style="western"><given-names>W.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wen</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Thiramanas</surname></string-name>, et&#160;al., &#8220;<article-title>Red&#8208;Light&#8208;Controlled Release of Drug&#8211;Ru Complex Conjugates From Metallopolymer Micelles for Phototherapy in Hypoxic Tumour Environments</article-title>,&#8221; <source>Advanced Functional Materials</source><volume>28</volume> (<year>2018</year>): <elocation-id>1804227</elocation-id>, <pub-id pub-id-type="doi">10.1002/adfm.201804227</pub-id>.</mixed-citation></ref><ref id="jbio70005-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="jbio70005-cit-0107"><string-name name-style="western"><given-names>S.</given-names><surname>Abyar</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Husiev</surname></string-name>, et&#160;al., &#8220;<article-title>Oxygen&#8208;Dependent Interactions Between the Ruthenium Cage and the Photoreleased Inhibitor in NAMPT&#8208;Targeted Photoactivated Chemotherapy</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>67</volume> (<year>2024</year>): <fpage>11086</fpage>&#8211;<lpage>11102</lpage>, <pub-id pub-id-type="doi">10.1021/acs.jmedchem.4c00589</pub-id>.<pub-id pub-id-type="pmid">38924492</pub-id><pub-id pub-id-type="pmcid">PMC11247496</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="jbio70005-cit-0108"><string-name name-style="western"><given-names>L.</given-names><surname>Paul</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Enkhbold</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Robinson</surname></string-name>, et&#160;al., &#8220;<article-title>Unravelling the Role of [Ru(Bpy)2(OH2)2]2+ Complexes in Photo&#8208;Activated Chemotherapy</article-title>,&#8221; <source>Journal of Inorganic Biochemistry</source><volume>235</volume> (<year>2022</year>): <elocation-id>111930</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2022.111930</pub-id>.<pub-id pub-id-type="pmid">35841722</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="jbio70005-cit-0109"><string-name name-style="western"><given-names>N.</given-names><surname>Mansour</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Mehanna</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Bodman&#8208;Smith</surname></string-name>, <string-name name-style="western"><given-names>C. F.</given-names><surname>Daher</surname></string-name>, and <string-name name-style="western"><given-names>R. S.</given-names><surname>Khnayzer</surname></string-name>, &#8220;<article-title>A Ru(II)&#8208;Strained Complex With 2,9&#8208;Diphenyl&#8208;1,10&#8208;Phenanthroline Ligand Induces Selective Photoactivatable Chemotherapeutic Activity on Human Alveolar Carcinoma Cells via Apoptosis</article-title>,&#8221; <source>Pharmaceuticals</source><volume>17</volume>, no. <issue>1</issue> (<year>2024</year>): <elocation-id>50</elocation-id>, <pub-id pub-id-type="doi">10.3390/ph17010050</pub-id>.<pub-id pub-id-type="pmcid">PMC10819265</pub-id><pub-id pub-id-type="pmid">38256884</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="jbio70005-cit-0110"><string-name name-style="western"><given-names>S.</given-names><surname>Qi</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Jin</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Hou</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Wang</surname></string-name>, and <string-name name-style="western"><given-names>Q.</given-names><surname>Zhou</surname></string-name>, &#8220;<article-title>Converting an Almost Noncytotoxic Ru(II) Complex With Photolabile Ligands Into a Highly Efficient PACT Agent</article-title>,&#8221; <source>Particle &amp; Particle Systems Characterization</source><volume>38</volume> (<year>2021</year>): <elocation-id>2100193</elocation-id>, <pub-id pub-id-type="doi">10.1002/ppsc.202100193</pub-id>.</mixed-citation></ref><ref id="jbio70005-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="jbio70005-cit-0111"><string-name name-style="western"><given-names>A. K.</given-names><surname>Renfrew</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Karges</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Scopelliti</surname></string-name>, et&#160;al., &#8220;<article-title>Towards Light&#8208;Activated Ruthenium&#8211;Arene (RAPTA&#8208;Type) Prodrug Candidates</article-title>,&#8221; <source>ChemBioChem</source><volume>20</volume> (<year>2019</year>): <fpage>2876</fpage>&#8211;<lpage>2882</lpage>, <pub-id pub-id-type="doi">10.1002/cbic.201900236</pub-id>.<pub-id pub-id-type="pmid">31102568</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="jbio70005-cit-0112"><string-name name-style="western"><given-names>Y.</given-names><surname>Luo</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Cao</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Zhong</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Xiong</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Zou</surname></string-name>, &#8220;<article-title>Organogold(III) Complexes Display Conditional Photoactivities: Evolving From Photodynamic Into Photoactivated Chemotherapy in Response to O<sub>2</sub> Consumption for Robust Cancer Therapy</article-title>,&#8221; <source>Angewandte Chemie International Edition</source><volume>61</volume>, no. <issue>45</issue> (<year>2022</year>): <elocation-id>e202212689</elocation-id>, <pub-id pub-id-type="doi">10.1002/anie.202212689</pub-id>.<pub-id pub-id-type="pmid">36109339</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="jbio70005-cit-0113"><string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Cui</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Zhang</surname></string-name>, and <string-name name-style="western"><given-names>W.</given-names><surname>Huang</surname></string-name>, &#8220;<article-title>Nanoparticulation of Prodrug Into Medicines for Cancer Therapy</article-title>,&#8221; <source>Advanced Science</source><volume>8</volume> (<year>2021</year>): <elocation-id>2101454</elocation-id>, <pub-id pub-id-type="doi">10.1002/advs.202101454</pub-id>.<pub-id pub-id-type="pmid">34323373</pub-id><pub-id pub-id-type="pmcid">PMC8456229</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="jbio70005-cit-0114"><string-name name-style="western"><given-names>R. V.</given-names><surname>Huis in't Veld</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Heuts</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>L. J.</given-names><surname>Cruz</surname></string-name>, <string-name name-style="western"><given-names>F. A.</given-names><surname>Ossendorp</surname></string-name>, and <string-name name-style="western"><given-names>M. J.</given-names><surname>Jager</surname></string-name>, &#8220;<article-title>Current Challenges and Opportunities of Photodynamic Therapy Against Cancer</article-title>,&#8221; <source>Pharmaceutics</source><volume>15</volume> (<year>2023</year>): <elocation-id>330</elocation-id>, <pub-id pub-id-type="doi">10.3390/pharmaceutics15020330</pub-id>.<pub-id pub-id-type="pmid">36839652</pub-id><pub-id pub-id-type="pmcid">PMC9965442</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="jbio70005-cit-0115"><string-name name-style="western"><given-names>M.</given-names><surname>Dymek</surname></string-name> and <string-name name-style="western"><given-names>E.</given-names><surname>Sikora</surname></string-name>, &#8220;<article-title>Liposomes as Biocompatible and Smart Delivery Systems &#8211; The Current State</article-title>,&#8221; <source>Advances in Colloid and Interface Science</source><volume>309</volume> (<year>2022</year>): <elocation-id>102757</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.cis.2022.102757</pub-id>.<pub-id pub-id-type="pmid">36152374</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="jbio70005-cit-0116"><string-name name-style="western"><given-names>Y.&#8208;Y.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Vecchio</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Avci</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Yin</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Garcia&#8208;Diaz</surname></string-name>, and <string-name name-style="western"><given-names>M. R.</given-names><surname>Hamblin</surname></string-name>, &#8220;<article-title>Melanoma Resistance to Photodynamic Therapy: New Insights</article-title>,&#8221; <source>Biological Chemistry</source><volume>394</volume> (<year>2013</year>): <fpage>239</fpage>&#8211;<lpage>250</lpage>, <pub-id pub-id-type="doi">10.1515/hsz-2012-0228</pub-id>.<pub-id pub-id-type="pmid">23152406</pub-id><pub-id pub-id-type="pmcid">PMC3545031</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="jbio70005-cit-0117"><string-name name-style="western"><given-names>A.</given-names><surname>Busetti</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Soncin</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Jori</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Kenney</surname></string-name>, and <string-name name-style="western"><given-names>M. A.</given-names><surname>Rodgers</surname></string-name>, &#8220;<article-title>Treatment of Malignant Melanoma by High&#8208;Peak&#8208;Power 1064 nm Irradiation Followed by Photodynamic Therapy</article-title>,&#8221; <source>Photochemistry and Photobiology</source><volume>68</volume> (<year>1998</year>): <fpage>377</fpage>&#8211;<lpage>381</lpage>.<pub-id pub-id-type="pmid">9747592</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="jbio70005-cit-0118"><string-name name-style="western"><given-names>P.</given-names><surname>Mroz</surname></string-name>, <string-name name-style="western"><given-names>Y.&#8208;Y.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Szokalska</surname></string-name>, et&#160;al., &#8220;<article-title>Stable Synthetic Bacteriochlorins Overcome the Resistance of Melanoma to Photodynamic Therapy</article-title>,&#8221; <source>FASEB Journal</source><volume>24</volume> (<year>2010</year>): <fpage>3160</fpage>&#8211;<lpage>3170</lpage>, <pub-id pub-id-type="doi">10.1096/fj.09-152587</pub-id>.<pub-id pub-id-type="pmid">20385618</pub-id><pub-id pub-id-type="pmcid">PMC2923353</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0119"><label>119</label><mixed-citation publication-type="journal" id="jbio70005-cit-0119"><string-name name-style="western"><given-names>E.&#8208;H.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>S.&#8208;J.</given-names><surname>Lim</surname></string-name>, and <string-name name-style="western"><given-names>M.&#8208;K.</given-names><surname>Lee</surname></string-name>, &#8220;<article-title>Chitosan&#8208;Coated Liposomes to Stabilize and Enhance Transdermal Delivery of Indocyanine Green for Photodynamic Therapy of Melanoma</article-title>,&#8221; <source>Carbohydrate Polymers</source><volume>224</volume> (<year>2019</year>): <elocation-id>115143</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.carbpol.2019.115143</pub-id>.<pub-id pub-id-type="pmid">31472877</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0120"><label>120</label><mixed-citation publication-type="journal" id="jbio70005-cit-0120"><string-name name-style="western"><given-names>C.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Guo</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Da</surname></string-name>, et&#160;al., &#8220;<article-title>UCNP@BSA@Ru Nanoparticles With Tumour&#8208;Specific and NIR&#8208;Triggered Efficient PACT Activity In&#160;Vivo</article-title>,&#8221; <source>Dalton Transactions</source><volume>50</volume> (<year>2021</year>): <fpage>7715</fpage>&#8211;<lpage>7724</lpage>, <pub-id pub-id-type="doi">10.1039/D1DT00777G</pub-id>.<pub-id pub-id-type="pmid">33983359</pub-id></mixed-citation></ref><ref id="jbio70005-bib-0121"><label>121</label><mixed-citation publication-type="book" id="jbio70005-cit-0121"><string-name name-style="western"><given-names>V.</given-names><surname>Ramu</surname></string-name>, <string-name name-style="western"><given-names>A. B.</given-names><surname>Auyeung</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Bonnet</surname></string-name>, &#8220;<part-title>Cytotoxicity of Metal&#8208;Based Photoactivated Chemotherapy (PACT)Photoactivated Chemotherapy (PACT) Compounds</part-title>,&#8221; in <source>Photodynamic Therapy: Methods and Protocols</source>, ed. <person-group person-group-type="editor"><string-name name-style="western"><given-names>M.</given-names><surname>Broekgaarden</surname></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><given-names>H.</given-names><surname>Zhang</surname></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><given-names>M.</given-names><surname>Korbelik</surname></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><given-names>M. R.</given-names><surname>Hamblin</surname></string-name></person-group>, and <person-group person-group-type="editor"><string-name name-style="western"><given-names>M.</given-names><surname>Heger</surname></string-name></person-group> (<publisher-name>Springer US</publisher-name>, <year>2022</year>), <fpage>245</fpage>&#8211;<lpage>258</lpage>, <pub-id pub-id-type="doi">10.1007/978-1-0716-2099-1_17</pub-id>.<pub-id pub-id-type="pmid">35505022</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>